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THERMOREVERSIBLE POLYMERS AND 
METHODS OF USE THEREOF 
CROSS - REFERENCE 
[ 0001 ] This application claims the benefit of U . S . Provi 
sional Patent Application No . 62 / 237 , 446 , filed Oct . 5 , 2015 , 
which application is incorporated herein by reference in its 
entirety . 
[ 0010 ] L is a linker ; 
[ 0011 ] X1 and X are each independently O or NH ; 
[ 0012 ] R ' is a lower alkyl ; 
[ 0013 ] R2 is H or methyl ; and 
[ 0014 ] G and G2 are each independently selected from a 
polymer segment , a terminal group , a linker and a linked 
modifying agent . 
[ 0015 ] In some embodiments of the first aspect , the ther 
moreversible polymer is described by formula ( II ) : 
INTRODUCTION 
[ 0002 ] Patients who suffer from a broad range of disorders 
involving tissue degeneration such as Parkinson ' s disease , 
a myocardial infarction ( heart attack ) , or liver failure 
could potentially benefit from implantation of new healthy 
cells or engineered tissues to replace damaged or diseased 
ones , a process known as cell replacement therapy . Stem 
cells have the unique abilities to replicate indefinitely in an 
immature state and to differentiate into various types of cells 
found in the body . Therefore , stem cells can be harnessed as 
the cell source for such cell replacement and tissue engi 
neering therapies . As such , systems and methods for scalable 
stem cell expansion and differentiation are of interest . 
( II ) 
HN oso o HN 
PEG , 
SUMMARY BI HNO RI NH2 mILl2 [ 0003 ] The present disclosure provides thermoreversible polymers , hydrogel compositions comprising the thermor 
eversible polymers , as well as methods of making and using 
the thermoreversible polymers . [ 0004 ] In a first aspect , the present disclosure provides a 
thermoreversible polymer comprising : a N - isopropylacryl 
amide co - monomer ; an alkyl [ meth ] acryl [ ate / amide ] co 
monomer ; and a PEG acrylamide co - monomer . In some 
cases , the alkyl [ meth ] acrylfate / amide ) co - monomer is an 
isobutyl methacrylate co - monomer . In some cases , the ther 
moreversible polymer further comprises a modifying acryl 
Fate / amide ) co - monomer comprising a linked functional 
group or a linked modifying agent . In some cases , the 
thermoreversible polymer comprises a segment described by 
formula ( 1 ) : 
[ 0016 ] wherein G ' , G2 , PEG » , R ' , L , Z2 and a - d are as 
described above . In some cases , d is 0 . In some cases , b > 0 . 
In some cases , a > 0 . 8 ; 0 . 1 > b > 0 ; and 0 . 2 > c > 0 . In some cases , 
R ! is selected from the group consisting of methyl , ethyl , 
propyl , butyl , pentyl , isopropyl , isobutyl , isopentyl , tert 
butyl , cyclopropyl , and cyclobutyl . In some cases , Z4 is a 
chemoselective functional group . In some cases , Z is a 
linked modifying agent , wherein the modifying agent is 
selected from a heparin , a hyaluronic acid , a specific binding 
member , a peptide , a nucleic acid , gelatin , fibronectin , 
collagen , laminin , bFGF , EGF , insulin , progesterone , glu 
cose , SDF thymosin beta - 4 , SHH , Noggin , Activin , TGF63 , 
FGF8 , BDNF , GDNF , NT3 , PDGF - AA and IGF - 1 . 
[ 0017 ] In some embodiments of the first aspect , a ther 
moreversible polymer is described by formula ( III ) : GITHUANG2 
HN 
( III ) to ox |L?2 GTA V 
HN 
HNO 
PEG , 
NH2 
[ 0005 ] wherein : 
[ 0006 ] a , b , c and d are molar fractions of the co - mono 
mers , wherein a and c are each greater than 0 ; [ 0007 ] PEG , is a polyethylglycol polymer ; 
[ 0008 ] Z is an optional terminal functional group or a 
linked modifying agent ; [ 0009 ] Z2 is a functional group or a linked modifying 
agent ; 
[ 0018 ] wherein G1 , G2 , PEG , and a - c are as described 
above . In some cases , a > 0 . 8 ; 0 . 1 > b > 0 ; and 0 . 2 > c > 0 . 
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[ 0019 ] In some embodiments of the first aspect , the ther 
moreversible polymer is described by the formula ( IV ) : [ 0022 ] In some cases , G ' and / or G2 comprises the follow ing structure : 
( IV ) 
GTAJO , 
HN 
PEG 
NH2 OH 
OS 
HN o 
TO HO 
OH ?? 
heparin 
[ 0020 ] wherein G ' , GP , PEG - , L and a - d are as described 
above . In some cases , G ' and G ? are each independently 
selected from a terminal group , a linker and a linked 
modifying agent . In some cases , G ' , Gº or Zº comprise a 
linked hyaluronic acid that is linked via conjugation to the 
carboxylic acid group of a hyaluronic acid monomer . In 
some cases , G ' , G or Z2 comprise the following structure : 
wa 
H -04
OH 
HO * 
?? 
o 
[ 0021 ] In some cases , Z2 comprises the following struc 
ture : 
10023 ] In some instances of the first aspect , e . g . , of any of 
Formula I - IV , the polymer has a MW of 5 to 500 kDa . In 
some cases , the PEG or PEG , , has a MW of 2 to 100 kDa . [ 0024 ] In a second aspect , the present disclosure provides 
a hydrogel composition , comprising : a thermoreversible 
polymer as described above or elsewhere herein ; and a 
buffered aqueous solution . In some cases , the hydrogel 
composition comprises cells . In some cases , the cells are 
stem cells selected from the group consisting of ( a ) adult 
stem cell derived from bone marrow , umbilical tissues , or 
placenta ; ( b ) neural stem cell ; ( c ) a progenitor cell derived 
from an embryonic stem cell ; and ( d ) embryonic stem cell . 
In some cases , the thermoreversible polymer is a solid at 20° 
C . or more . In some cases , the thermoreversible polymer is 
a solid at 37° C . In some cases , the thermoreversible 
polymer is a liquid at 30° C . or less . In some cases , the 
thermoreversible polymer is a liquid at 4° C . 
[ 0025 ] In a third aspect , the present disclosure provides a 
method of growing cells , the method comprising : introduc 
ing cells into a hydrogel composition of the second aspect as 
described above , or a hydrogel composition as described 
elsewhere herein , to produce a culturing mixture comprising 
a cell construct ; and incubating the culturing mixture under 
conditions suitable for growth of the cells . 
[ 0026 ] In a fourth aspect , the present disclosure provides 
a method of differentiating stem cells , the method compris 
ing : introducing stem cells into a hydrogel composition of 
the second aspect as described above , or a hydrogel com 
position as described elsewhere herein , to produce a cultur 
ing mixture comprising a cell construct ; and incubating the 
culturing mixture under conditions suitable for differentia 
tion of the stem cells . [ 0027 ] In a fourth aspect , the present disclosure provides 
a method of preparing a thermoreversible copolymer as 
described in the first aspect , above , or elsewhere herein , the 
method comprising : a ) co - polymerizing : i ) an alkyl meth 
acrylate in which the alkyl is one of methyl , ethyl , propyl , 
butyl , pentyl , isopropyl , isobutyl , isopentyl , tert - butyl , 
cyclopropyl , and cyclobutyl ; and ii ) acrylic acid N - hydroxy 
succinimide ester to make a copolymer comprising an 
acrylic backbone ; b ) contacting the copolymer with isopro 
pylamine to convert a first portion of the N - hydroxysuccin 
um 
OH 
TOHO 
?? 
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imide ester groups to N - isopropylamine groups ; and c ) 
contacting the copolymer with a diamino - PEG to convert a 
second portion of the N - hydroxysuccinimide ester groups to 
N - PEG - NH , groups . In some cases , the method further 
comprises contacting the copolymer with an amino linker to 
convert a third portion of the N - hydroxysuccinimide ester 
groups to N - linker - Z2 groups , where Z² is a chemoselective 
functional group . 
BRIEF DESCRIPTION OF THE DRAWINGS 
[ 0028 ] FIG . 1 depicts the steps of cell incorporation and 
removal from a thermoreversible polymer hydrogel . 
10029 ] FIG . 2 depicts PNIPAM amide groups hydrogen 
bonding with water below the lower critical solution tem 
perature ( LCST ) and hydrogen bonding with each other 
above the LCST , creating hydrophobic microdomains . 
[ 0030 ] FIG . 3 shows a scheme for the synthesis of an 
exemplary polymer , PNIPAM - PEG - Isobutyl methacrylate . 
The same synthesis strategy can be performed to incorporate 
different methacrylate groups . A moiety of interest , such as 
heparin can be attached via the free amine groups of the 
PEG . 
[ 0031 ] FIG . 4 illustrates that small molecular weight PNI 
PAM - PEG - Butyl methacrylates do not produce stiff gels 
using a variety of PEGs of various lengths or concentration . 
[ 0032 ] FIG . 5 illustrates that higher molecular weight 
PNIPAM - PEG - BuMeA copolymers can make gels that are 
stiff but which do not re - liquefy after being held at a 
temperature of 37° C . for more than a few hours . 
[ 0033 ] FIG . 6 illustrates the results of using methyl , ethyl 
or isobutyl methacrylate during synthesis to prepare stiff 
gels with higher molecular weights . 
[ 0034 ] FIG . 7A - 7D shows images of cell aggregates grow 
ing in an exemplary PNIPAM - PEG - Isobutyl methacrylate 
hydrogel : ( FIG . 7A ) at day 1 ; ( FIG . 7B ) at day 2 ; ( FIG . 7C ) 
at day 3 ; and ( FIG . 7D ) at day 4 . 
[ 0035 ] FIG . 8A - 8C provides images of antibody stained 
cells for : ( FIG . 8A ) DAPI ; ( FIG . 8B ) Nanog ; and ( FIG . 8C ) 
Oct4 ; demonstrating the pluripotency of cells after growing 
in an exemplary hydrogels . 
[ 0036 ] FIG . 9 depicts a scheme for the preparation of a 
PNIPAM - PEG - Isobutyl methacrylate - thiol thermorevers 
ible polymer . 
[ 0037 ] FIG . 10 illustrates heparin functionalization and 
attachment to an exemplary PNIPAM - PEG - IsoBuMeA - thiol 
polymer . 
[ 0038 ] FIG . 11 depicts a H NMR spectrum showing hepa 
rin conjugated to an exemplary PNIPAM - PEG - Isobutyl 
methacrylate polymer . 
[ 0039 ] FIG . 12 depicts an exemplary conjugation scheme 
including hyaluronic acid divinyl sulfone chemistry with a 
PNIPAM - thiol polymer . 
[ 0040 ] FIG . 13 depicts an exemplary scheme for function 
alizing hyaluronic acid with a linked maleimide group for 
subsequent thiol conjugation chemistry . 
10041 ] FIG . 14 depicts an exemplary scheme for prepara 
tion of hyaluronic acid ( HA ) conjugates with an exemplary 
PNIPAM - BuMeA thiol polymer using a vinyl sulfone / thiol 
linkage . 
[ 0042 ] FIG . 15 provides a rheology plot of an exemplary 
hyaluronic acid - vinyl sulfone - PNIPAM thermoreversible 
polymer with and without a butyl methacrylate co - monomer 
showing that incorporation of butyl methacrylate can lower 
LCST while maintaining stiffness around 1 kPa . 
[ 0043 ] FIG . 16 depicts an exemplary scheme for synthesis 
of an exemplary PNIPAM - BuMeA - thiol polymer including 
thiol groups present on sidechain linkers throughout the 
polymer chain . 
[ 0044 ] FIG . 17 provides a rheology plot of modulus vs . 
temperature for exemplary HA - PNIPAM polymers prepared 
using various ratios of PNIPAM : HA by weight . As less 
PNIPAM is added , the gels become softer and have a higher 
lower critical solution temperature ( LCST ) . 
[ 0045 ] FIG . 18 provides a rheology plot of modulus vs . 
temperature showing that a smaller MW Hyaluronic acid 
can produce softer and higher LCST gels . [ 0046 ] FIG . 19 depicts an exemplary scheme for heparin 
addition to hyaluronic acid . 
[ 0047 ] FIG . 20 summarizes rheology data illustrating the 
increased storage modulus with larger PEG molecular 
weight for copolymers containing isobutyl methacrylate and 
butyl methacrylate . 
[ 0048 ] FIG . 21 depicts an increase in storage modulus 
with increasing PNIPAM - PEG - BuMeA or PNIPAM - PEG 
IsoBuMeA polymer size ( based on ratio of solvents during 
synthesis ) . 
[ 0049 ] FIG . 22 illustrates the increase in storage modulus 
as alkyl chain of methacrylate increases ( between methyl , 
ethyl , and isobutyl methacrylates ) . 
[ 0050 ] FIG . 23A - 23D shows images of single cells and 
cell aggregates growing in an exemplary PNIPAM - PEG 
Isobutyl methacrylate hydrogel : H9 LESC cell growth from 
day 1 as small aggregates ( FIG . 23A ) to larger aggregates 
after 4 days ( FIG . 23B ) . TCTF iPSCs pictures after 1 day as 
single cells ( FIG . 23C ) and after 4 days ( FIG . 23D ) . Scale 
bars are all 100 min . 
[ 0051 ] FIG . 24A - 24B shows hPSC pluripotency marker 
expression after cells were grown for multiple passages 
within PNIPAM - PEG - Isobutyl methacrylate hydrogels . 
FIG . 24A : Example images of TCTF iPSCs and H1 hESCs 
staining positive for pluripotency markers Oct4 and Nanog , 
scale bars are 100 um . FIG . 24B : Statistics on cells grown 
for 1 - 3 passages within the gels are > 95 % Oct4 and Nanog 
positive . 
[ 0052 ] FIG . 25A - 25C shows ' H NMR spectra of PNI 
PAM - SH ( FIG . 25A ) , Hyaluronic acid - vinyl sulfone ( FIG . 
25B ) , and Hyaluronic acid - PNIPAM ( FIG . 25C ) . 
[ 0053 ] FIG . 26A - 26C illustrates rheological effects of 
hydrogels based on HA size , component ratios , polymer 
concentration , and BuMeA content . FIG . 26A - 26C : Storage 
modulus at 37° C . ( black squares ) and LCST ( grey triangles ) 
as a function of HA molecular weight ( FIG . 26A ) , PNI 
PAAM : HA ratio ( FIG . 26B ) , Polymer concentration in solu 
tion ( FIG . 26C ) . All error bars represent average storage 
modulus between 35 - 39° C . and concentrations are 10 w / v 
% unless otherwise noted . Panel A gels all were - 30 % 
functionalized . FIG . 26C shows the same 1 MDa 40 % 
HA - PNIPAAm gel at different concentrations . 
[ 0054 ] FIG . 27A - 27D shows images of cell growth for 
different cell lines growing in HA - PNIPAM hydrogels : FIG . 
27A : Day 1 TCTF single cells FIG . 27B : Day 4 in 4th round 
TCTF plated as single cells FIG . 27C . Day 4 H9 cells plated 
as single cells for 1 round FIG . 27D . Day 4 H1 cells plated 
as single cells for 1 round . Scale bars are all 200 um . 
[ 0055 ] FIG . 28 shows the TCTF iPSC growth capability 
within the HA - PNIPAM hydrogels through multiple pas 
sages . 
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[ 0056 ] FIG . 29A - 29C depicts pluripotency markers Oct4 
and Nanog for multiple cell lines ( FIG . 29A ) as well as 
expression of all three germ layers ( FIG . 29B ) by embryoid 
body differentiation analysis ( FIG . 29C ) after cells were 
grown for multiple passages within HA - PNIPAM hydrogels . 
[ 0057 ] FIG . 30A - 30D shows the growth of neural stem 
cells within HA - PNIPAM gels and stains for multipotency 
marker Sox2 . 
DEFINITIONS 
[ 0058 ] The following terms have the following meanings 
unless otherwise indicated . Any undefined terms have their 
art recognized meanings . 
[ 0059 ] The term “ cell culture ” or “ culturing of cells ” 
refers to maintaining , transporting , isolating , culturing , 
propagating , passaging or differentiating of cells or tissues . 
Cells can be in any arrangement such as individual cells , 
monolayers , cell clusters or spheroids or as tissue . 
10060 ] As used herein , the term " linker ” or “ linkage " 
refers to a linking moiety that connects two groups and has 
a backbone of 100 atoms or less in length . A linker or linkage 
may be a covalent bond that connects two groups or a chain 
of between 1 and 100 atoms in length , for example of 1 , 2 , 
3 , 4 , 5 , 6 , 8 , 10 , 12 , 14 , 16 , 18 or 20 carbon atoms in length , 
where the linker may be linear , branched , cyclic or a single 
atom . In certain cases , one , two , three , four or five or more 
carbon atoms of a linker backbone may be optionally 
substituted with a sulfur , nitrogen or oxygen heteroatom . 
The bonds between backbone atoms may be saturated or 
unsaturated , usually not more than one , two , or three unsatu 
rated bonds will be present in a linker backbone . The linker 
may include one or more substituent groups , for example 
with an alkyl , aryl or alkenyl group . A linker may include , 
without limitations , poly ( ethylene glycol ) ; ethers , thioeth 
ers , tertiary amines , alkyls , which may be straight or 
branched , e . g . , methyl , ethyl , n - propyl , 1 - methylethyl ( iso 
propyl ) , n - butyl , n - pentyl , 1 , 1 - dimethylethyl ( t - butyl ) , and 
the like . The linker backbone may include a cyclic group , for 
example , an aryl , a heterocycle or a cycloalkyl group , where 
2 or more atoms , e . g . , 2 , 3 or 4 atoms , of the cyclic group 
are included in the backbone . A linker may be cleavable or 
non - cleavable . 
[ 0061 ] “ Alkyl ” refers to monovalent saturated aliphatic 
hydrocarbyl groups having from 1 to 10 carbon atoms and 
such as 1 to 6 carbon atoms , or 1 to 5 , or 1 to 4 , or 1 to 3 
carbon atoms . In some cases , a “ lower alkyl ” is an alkyl 
group having 1 to 6 carbon atoms . This term includes , by 
way of example , linear and branched hydrocarbyl groups 
such as methyl ( CH3 – ) , ethyl ( CH3CH2 – ) , n - propyl ( CH2CH2CH2 – ) , isopropyl ( ( CH3 ) 2CH — ) , n - butyl ( CH2CH2CH2CH2 – ) , isobutyl ( ( CH3 ) 2CHCH2 – ) , sec - bu 
tyl ( ( CH3 ) ( CH2CH2CH — ) , t - butyl ( ( CH3 ) 3C — ) , n - pentyl ( CH3CH2CH2CH2CH2 – ) , and neopentyl ( ( CH3 ) 3CCH2 - ) . [ 0062 ] The term “ substituted alkyl ” refers to an alkyl 
group as defined herein wherein one or more carbon atoms 
in the alkyl chain have been optionally replaced with a 
heteroatom such as O — , N — S , - S ( O ) , ( where n 
is 0 to 2 ) , - NR - ( where R is hydrogen or alkyl ) and 
having from 1 to 5 substituents selected from the group 
consisting of alkoxy , substituted alkoxy , cycloalkyl , substi 
tuted cycloalkyl , cycloalkenyl , substituted cycloalkenyl , 
acyl , acylamino , acyloxy , amino , aminoacyl , aminoacyloxy , 
oxyaminoacyl , azido , cyano , halogen , hydroxyl , oxo , thio - 
keto , carboxyl , carboxylalkyl , thioaryloxy , thioheteroary 
loxy , thioheterocyclooxy , thiol , thioalkoxy , substituted thio 
alkoxy , aryl , aryloxy , heteroaryl , heteroaryloxy , 
heterocyclyl , heterocyclooxy , hydroxyamino , alkoxyamino , 
nitro , SO - alkyl , SO - aryl , - SO - heteroaryl , SO2 
alkyl , SO2 - aryl , SO2 - heteroaryl , and — NR “ R ” , 
wherein R and R may be the same or different and are chosen 
from hydrogen , optionally substituted alkyl , cycloalkyl , 
alkenyl , cycloalkenyl , alkynyl , aryl , heteroaryl and hetero 
cyclic . 
[ 0063 ] As used herein , the terms “ chemoselective func 
tional group ” and “ chemoselective tag ” are used inter 
changeably and refer to chemoselective reactive groups that 
selectively react with one another to form a covalent bond . 
Chemoselective functional groups of interest include , but 
are not limited to , two thiol groups , thiols and maleimide or 
iodoacetamide , as well as groups that can react with one 
another via Click chemistry , e . g . , azide and alkyne groups 
( e . g . , cyclooctyne groups ) . Chemoselective functional 
groups of interest , include , but are not limited to , thiols , 
alkyne , a cyclooctyne , an azide , a phosphine , a maleimide , 
an alkoxyamine , an aldehyde and protected versions thereof , 
and percursors thereof . In certain embodiments , the che 
moselective functional group is a thiol . 
[ 0064 ] As used , herein the lower critical solution tempera 
ture ( LCST ) or lower consolute temperature refers to the 
critical temperature below which the components of a mix 
ture are miscible for all compositions . The word lower in the 
term indicates that the LCST is a lower bound to a tem 
perature interval of partial miscibility , or miscibility for 
certain compositions only . 
[ 0065 ] Before the present invention is further described , it 
is to be understood that this invention is not limited to 
particular embodiments described , as such may , of course , 
vary . It is also to be understood that the terminology used 
herein is for the purpose of describing particular embodi 
ments only , and is not intended to be limiting , since the 
scope of the present invention will be limited only by the 
appended claims . 
[ 0066 ] Where a range of values is provided , it is under 
stood that each intervening value , to the tenth of the unit of 
the lower limit unless the context clearly dictates otherwise , 
between the upper and lower limit of that range and any 
other stated or intervening value in that stated range , is 
encompassed within the invention . The upper and lower 
limits of these smaller ranges may independently be 
included in the smaller ranges , and are also encompassed 
within the invention , subject to any specifically excluded 
limit in the stated range . Where the stated range includes one 
or both of the limits , ranges excluding either or both of those 
included limits are also included in the invention . 
[ 0067 ] Unless defined otherwise , all technical and scien 
tific terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which this 
invention belongs . Although any methods and materials 
similar or equivalent to those described herein can also be 
used in the practice or testing of the present invention , the 
preferred methods and materials are now described . All 
publications mentioned herein are incorporated herein by 
reference to disclose and describe the methods and / or mate 
rials in connection with which the publications are cited . 
[ 0068 ] It must be noted that as used herein and in the 
appended claims , the singular forms “ a , ” “ an , ” and “ the ” 
include plural referents unless the context clearly dictates 
otherwise . Thus , for example , reference to “ a thermorevers 
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ible polymer ” includes a plurality of such polymers and 
reference to " the hydrogel composition ” includes reference 
to one or more hydrogel compositions and equivalents 
thereof known to those skilled in the art , and so forth . It is 
further noted that the claims may be drafted to exclude any 
optional element . As such , this statement is intended to serve 
as antecedent basis for use of such exclusive terminology as 
" solely , " " only ” and the like in connection with the recita 
tion of claim elements , or use of a “ negative ” limitation . 
[ 0069 ] It is appreciated that certain features of the inven 
tion , which are , for clarity , described in the context of 
separate embodiments , may also be provided in combination 
in a single embodiment . Conversely , various features of the 
invention , which are , for brevity , described in the context of 
a single embodiment , may also be provided separately or in 
any suitable sub - combination . All combinations of the 
embodiments pertaining to the invention are specifically 
embraced by the present invention and are disclosed herein just as if each and every combination was individually and 
explicitly disclosed . In addition , all sub - combinations of the 
various embodiments and elements thereof are also specifi 
cally embraced by the present invention and are disclosed 
herein just as if each and every such sub - combination was 
individually and explicitly disclosed herein . 
[ 0070 ] The publications discussed herein are provided 
solely for their disclosure prior to the filing date of the 
present application . Nothing herein is to be construed as an 
admission that the present invention is not entitled to ante 
date such publication by virtue of prior invention . Further , 
the dates of publication provided may be different from the 
actual publication dates which may need to be independently 
confirmed . 
[ meth ] acryl [ ate / amide ) co - monomer ” refers to a co - mono 
mer that is an alkyl acrylate , an alkyl methacrylate , an alkyl 
acrylamide or an alkyl methacrylamide . In some instances , 
the alkyl [ meth ] acryl [ ate / amide ] co - monomer is an isobutyl 
methacrylate co - monomer . 
[ 0075 ] As used herein , the term PEG acrylamide co 
monomer refers to a N - alkyl acrylamide further substituted 
on the alkyl sidechain with a polyethylene glycol ( PEG ) or 
modified polyethylene glycol . In some cases , a PEG poly 
meric group includes water - soluble repeat units comprising 
an ethylene oxide of the formula ( CH2CH20 ) or ( 0 CH , CH , ) . The number of such water - soluble 
repeat units can vary significantly , with the number of such 
units being from 2 to 500 , 2 to 400 , 2 to 300 , 2 to 200 , 2 to 
100 , for example from 2 to 50 . A modified PEG can include 
any convenient terminal modifications , such as substitution 
or modification with a linked functional group such as an 
amine , a thiol or a carboxylic acid , e . g . , capable of conju 
gation with a modifying agent of interest . 
[ 0076 ] In some embodiments , the thermoreversible poly 
mer further comprises a modifying acrylfate / amide ) co 
monomer comprising a linked functional group or a linked 
modifying agent . As used herein , by modifying acryl [ ate / 
amide ) co - monomer is meant a substituted alkyl acrylate or 
a substituted N - alkyl acrylamide co - monomer , which can be 
substituted with an optional linker terminated with a func 
tional group and / or a linked modifying agent . In certain 
embodiments , the thermoreversible polymer lacks a PEG 
acrylamide co - monomer . 
[ 0077 ] In some embodiments , the thermoreversible poly 
mer comprises a polymeric segment described by formula 
( I ) : 
DETAILED DESCRIPTION ( 1 ) 
nh 
HN NO HNO N x1 
- 
PEG , MH -N
[ 0071 ] The present disclosure provides thermoreversible 
polymers , hydrogel compositions comprising the thermor 
eversible polymers , as well as methods of making and using 
the thermoreversible polymers . 
[ 0072 ] Thermoreversible Polymers [ 0073 ] Aspects of the present disclosure include thermor 
eversible polymers ( also referred to as “ thermosensitive 
polymers ” or “ thermoresponsive polymers ” ) . As used 
herein , the term " thermoreversible ” is used to refer to a 
polymeric material that exhibits a drastic change in its 
physical property with a change in temperature . Thermor 
eversible polymers belong to the class of stimuli - responsive 
materials . In some cases , a thermoreversible polymer is 
distinguished from a temperature - sensitive ( e . g . , thermosen 
sitive ) material , which can change physical properties con 
tinuously with environmental conditions . A thermorespon 
sive polymer can display a miscibility gap in its 
temperature - composition diagram . Depending on whether 
the miscibility gap is found at high or low temperatures , an 
upper or lower critical solution temperature exists , respec 
tively ( abbreviated UCST or LCST , respectively ) . For 
example , at a temperature below the LCST , a thermorespon 
sive polymer can be miscible with an aqueous solution in 
which it dissolves . At a temperature above the LCST , the 
thermoresponsive polymer forms a solid , semi -solid , or gel 
having a three dimensional structure . 
[ 0074 ] The subject thermoreversible polymers can include 
a polymer including N - isopropylacrylamide co - monomer , 
an alkyl [ methJacrylfate / amide ] co - monomer ; and a PEG 
acrylamide co - monomer . As used herein , the term “ an alkyl 
wherein : 
[ 0078 ] a , b , c and d are molar fractions of the co 
monomers ( e . g . , in some cases , a and c are each greater 
than 0 ) ; 
[ 0079 ] PEG , is a polyethylglycol polymer ; 
[ 0080 ] Z ' is an optional terminal functional group or a linked modifying agent ; 
[ 0081 ] Z is a functional group or a linked modifying 
agent ; 
[ 0082 ] L is a linker ; [ 0083 ] X and X² are each independently O or NH ; 
[ 0084 ] R ' is an alkyl or a substituted alkyl ( e . g . , a lower 
alkyl or a substituted lower alkyl ) ; 
[ 0085 ] R² is H or methyl ; and 
[ 0086 ] G and G ? are each independently selected from 
a polymer segment , a terminal group , a linker and a 
linked modifying agent ( e . g . , a hyaluronic acid ) . 
[ 0087 ] As used here , the term “ modifying agent ” refers to 
any convenient agent that provides for a desirable property 
of interest ( e . g . , a desirable physical and / or biological prop 
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erty ) and which is capable of conjugation to the thermor 
eversible polymer , e . g . , via a chemoselective functional 
group on a sidechain linker or terminal of the polymer . Such 
an agent may belong to the class of small molecule , protein , 
peptide , sugar , polynucleotide , etc . Modifying agents of 
interest include , but are not limited to , a ligand , a substrate , 
an enzyme , a pharmaceutical agent ( e . g . , a chemotherapeutic 
agent ) , a plasmid , a polynucleotide , a bioactive peptide , an 
antibody , a biomarker , a bio - sensor , a catalyst , an element , 
a cell targeting agent , small drug molecules , fluorescent / 
radioactive / optical imaging agents , peptides / proteins / en 
zymes , nucleic acids ( siRNA / RNA / DNA / etc . ) , metal based 
compounds / catalysts , site - specific cellular targeting agents ( compounds / ligands / antibodies / etc . ) and smart adjuvants , 
gene therapy vectors . In certain embodiments , the modifying 
agent is selected from a heparin , a hyaluronic acid , a specific 
binding member , a peptide , a nucleic acid , gelatin , fibronec 
tin , collagen , laminin , bFGF , EGF , insulin , progesterone , 
glucose , thymosin beta - 4 , SHH , Noggin , Activin , TGFb3 , 
FGF8 , BDNF , GDNF , NT3 , PDGF - AA and IGF - 1 . In certain 
instances , the modifying agent is a cytokine , a BMP family 
member ( e . g . , TGFbeta or activin ) , a neutrophin ( e . g . , NT3 
or BDNF ) or a hedgehog protein ( e . g . , SHH ) . 
[ 0088 ] Any convenient methods may be utilized in con jugating a modifying agent to a thermoreversible polymer . 
Conjugation methods and chemistries of interest include , but 
are not limited to , those described by Greg Hermanson in 
Bioconjugate Techniques ( Third edition ) 2013 , Academic 
Press . In certain embodiments , the modifying agent is a 
protein . In certain embodiments , the modifying agent is a 
peptide . In certain embodiments , the modifying agent is 
peptidic and can be conjugated to the thermoreversible 
polymer ( e . g . , via a terminal and / or a sidechain functional 
group ) by covalent attachment to the N - terminal or C - ter 
minal or the peptidic agent , or covalent attachment to an 
amino acid sidechain ( e . g . , an amino , thiol , hydroxyl , car 
boxylic acid or phenol - containing amino acid sidechain 
group , or a derivative thereof ) . In certain embodiments , the 
modifying agent is a heparin . In certain embodiments , the 
heparin modifying agent is linked via a vinvylsulfone / thiol 
linkage . In certain instances , the heparin can be linked to the 
subject polymers via conjugation to a carboxylic acid group 
of the heparin . For example , FIG . 19 depicts exemplary 
methods of preparing a heparin - thiol derivative and a 
hyaluronic acid - vinyl sulfone derivative that finds use in 
conjugation to the subject thermoreversible polymer . In 
certain embodiments , heparin can be attached via an amine 
group of the thermoreversible polymer . In certain embodi 
ments , two or more modifying agents ( e . g . , a heparin and a 
hyaluronic acid ) may be linked to each other in addition to 
a thermoreversible polymer . 
[ 0089 ] In some embodiments of formula ( I ) , b is 0 . In 
some embodiments of formula ( I ) , b > 0 . In some embodi 
ments of formula ( I ) , b < 0 . 5 . In some embodiments of 
formula ( 1 ) , b < 0 . 4 . In some embodiments of formula ( 1 ) , 
b < 0 . 3 . In some embodiments of formula ( I ) , b < 0 . 2 . In some 
embodiments of formula ( 1 ) , b < 0 . 1 . In some embodiments of 
formula ( I ) , O < b < 0 . 1 . In some embodiments of formula ( I ) , 
O < b < 0 . 05 . In some embodiments of formula ( I ) , O < b < 0 . 02 . 
10090 ] In some embodiments of formula ( I ) , d is 0 . In 
some embodiments of formula ( I ) , d > 0 . In some embodi 
ments of formula ( I ) , d < 0 . 5 . In some embodiments of 
formula ( I ) , d < 0 . 4 . In some embodiments of formula ( I ) , 
d < 0 . 3 . In some embodiments of formula ( I ) , d < 0 . 2 . In some 
embodiments of formula ( I ) , d < 0 . 1 . In some embodiments of 
formula ( I ) , O < d < 0 . 1 . In some embodiments of formula ( I ) , 
O < d < 0 . 05 . 
[ 0091 ] In some embodiments of formula ( I ) , a > 0 . 3 . In 
some embodiments of formula ( I ) , a > 0 . 4 . In some embodi 
ments of formula ( 1 ) , a > 0 . 5 . In some embodiments of 
formula ( I ) , a > 0 . 6 . In some embodiments of formula ( I ) , 
a > 0 . 7 . In some embodiments of formula ( 1 ) , a > 0 . 8 . In some 
embodiments of formula ( I ) , a > 0 . 9 . 
[ 0092 ] In some embodiments of formula ( I ) , c > 0 . 1 . In 
some embodiments of formula ( 1 ) , c > 0 . 2 . In some embodi 
ments of formula ( 1 ) , c > 0 . 3 . In some embodiments of 
formula ( I ) , c < 0 . 3 . In some embodiments of formula ( 1 ) , 
c < 0 . 2 . In some embodiments of formula ( I ) , 0 < c < 0 . 2 . In 
some embodiments of formula ( I ) , O < c < 0 . 15 . In some 
embodiments of formula ( I ) , c = 0 . 
[ 0093 ] In some embodiments of formula ( I ) , a > 0 . 9 , 
O < b < 0 . 02 , 0 < c < 0 . 2 and O < d < 0 . 05 . 
[ 0094 ] In some embodiments of formula ( I ) , a > 0 . 95 . In 
some embodiments of formula ( I ) , O < b < 0 . 01 . In some 
embodiments of formula ( I ) , O < c < 0 . 1 . In some embodiments 
of formula ( I ) , O < d < 0 . 03 . In some embodiments of formula 
( I ) , a > 0 . 95 , 0 < b < 0 . 01 , 0 < c < 0 . 1 and 0 < d < 0 . 03 . 
10095 ] In some embodiments of formula ( I ) , a > 0 . 95 , 
O < b < 0 . 01 , O < c < 0 . 07 and < d < 0 . 02 . In some embodiments 
of formula ( I ) , a > 0 . 95 . In some embodiments of formula ( I ) , 
O < b < 0 . 01 . In some embodiments of formula ( I ) , 0 < c < 0 . 07 . 
In some embodiments of formula ( I ) , 0 < d < 0 . 02 . [ 0096 ] Any convenient poly ( ethylglycol ) ( PEG ) poly 
meric groups may be utilized as a sidechain in the thermor 
eversible polymers of Formula ( I ) . In some embodiments of 
formula ( I ) , PEG , is a polyethylglycol polymer having a 
MW of 2 kDa or greater , such as 2 kDa to 100 kDa , or 2 KD 
to 10 kDa , or 3 kDa to 10 kDa , such as 3400 Da . The PEG , 
group can be modified with any convenient groups , includ 
ing terminal modifications . In some instances , the PEG , 
group is modified with a terminal group Z . In some 
embodiments , PEG , , includes a terminal carboxylic acid . In 
some embodiments , PEG , includes a terminal amine group . 
In some embodiments , Z ' is a linked modifying agent ( e . g . , 
as described herein ) . 
[ 0097 ] Any convenient chemoselective functional groups 
capable of conjugation with a compatible functional group 
on another moiety of interest may find use as terminal group 
Z2 in the subject a modifying acrylfate / amide ] co - monomer . 
In some embodiments , Z2 is a functional group selected from 
an amino , a thiol , a carboxylic acid , a maleimide , a vinyl 
sulfone , a haloacetyl , an azide , an alkyne ( e . g . , a cyclooc 
tyne ) , and protected versions thereof . In some embodiments 
of formula ( I ) , Zº is a thiol . In some embodiments of formula 
( I ) , Z2 is an azide . In some embodiments of formula ( I ) , Z2 
is a maleimide . A variety of methods and reagents may find 
use in conjugating a modifying agent of interest to the 
terminal of a PEG , sidechain group . In some embodiments , 
Z ' is a linked modifying agent ( e . g . , as described herein ) . In 
some embodiments , heparin can be conjugated to an amine 
group of the PEG side chain in the thermoreversible poly 
mer . 
10098 ] Any convenient linkers may be utilized in the 
subject thermoreversible polymers . In certain embodiments , 
the linker ( L ) includes a polymer . For example , the polymer 
may include a polyalkylene glycol and derivatives thereof , 
including polyethylene glycol , methoxypolyethylene glycol , 
polyethylene glycol homopolymers , polypropylene glycol 
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homopolymers , copolymers of ethylene glycol with propyl 
ene glycol ( e . g . , where the homopolymers and copolymers 
are unsubstituted or substituted at one end with an alkyl 
group ) , polyvinyl alcohol , polyvinyl ethyl ethers , polyvi 
nylpyrrolidone , combinations thereof , and the like . In cer 
tain embodiments , the polymer is a polyalkylene glycol . In 
certain embodiments , the polymer is a polyethylene glycol . 
Linkers of interest include , but are not limited to , units of 
polymers such as polyethylene glycols , polyethylenes and 
polyacrylates , amino acid residue ( s ) , carbohydrate - based 
polymers or carbohydrate residues and derivatives thereof , 
polynucleotides , alkyl groups , aryl groups , heterocycle 
groups , cleavable linker groups , combinations thereof , and 
substituted versions thereof . 
[ 0099 ] In some embodiments , the linker includes a cleav 
able moiety ( e . g . , a chemically cleavable moiety , an enzy 
matically cleavable moiety ( such as , but not limited to , a 
protease cleavable moiety , a glucuronidase cleavable moi 
ety , a beta - lactamase cleavable moiety , etc . ) , a photocleav 
able moiety , and the like . In certain embodiments , the 
cleavable moiety is a para - amino - benzyloxycarbonyl group , 
a meta - amino - benzyloxycarbonyl group , a para - amino - ben 
zyloxy group , a meta - amino - benzyloxy group , para - amin 
obenzyl , an acetal group , a disulfide , a hydrazine , a protease 
cleavable moiety , a glucuronidase cleavable moiety , a beta 
lactamase cleavable moiety , or an ester . 
[ 0100 ] In some embodiments of formula ( I ) , Rl is a lower 
alkyl or a substituted lower alkyl . In some embodiments of 
formula ( I ) , R1 is a lower alkyl selected from the group 
consisting of methyl , ethyl , propyl , butyl , pentyl , isopropyl , 
isobutyl , isopentyl , tert - butyl , cyclopropyl , and cyclobutyl . 
In certain embodiments , Rl is methyl . In certain embodi 
ments , R ' is ethyl . In certain embodiments , R ' is propyl . In 
certain embodiments , R is butyl . In certain embodiments , 
R ! is pentyl . In certain embodiments , Rl is isopropyl . In 
certain embodiments , R is isobutyl . In certain embodi 
ments , R ' is isopentyl . In certain embodiments , R ' is tert 
butyl . In certain embodiments , Rl is cyclopropyl . In certain 
embodiments , R ' is cyclobutyl . 
[ 0101 ] In some embodiments of formula ( I ) , R2 is H . In 
some embodiments of formula ( I ) , R is methyl . 
[ 0102 ] In some embodiments of formula ( I ) , G1 and / or G2 
are each independently a further polymer segment , such as 
a polyacrylic acid or polyacrylamide polymer . In certain 
cases of formula ( I ) , G ' and / or G ’ are each independently a 
terminal group , e . g . , H , an alkyl or a substituted alkyl . In 
certain cases , the terminal groups are groups which are 
produced as a result of any convenient method of polymer 
ization of the subject co - monomers described herein . In 
some embodiments of formula ( I ) , G1 and / or G² comprise a 
linker that may include a chemoselective functional group . 
In some embodiments of formula ( 1 ) , G and / or G² comprise 
a linked modifying agent ( e . g . , as described herein ) . Any 
convenient methods of derivatizing or modifying polymers 
may be utilized to provide for installation of a G and / or Gº 
group of interest at the terminals of the subject polymers . In 
certain cases , G and / or G² group comprises a linked modi 
fying agent ( e . g . , a hyaluronic acid ) . 
[ 0103 ] In some embodiments , the thermoreversible poly 
mer comprises a polymeric segment described by formula 
( II ) : 
[ 0104 ] wherein G1 , G² , PEG » , R1 , L , Z ? and a - d are as 
described for formula ( I ) . 
[ 0105 ] In some embodiments , the thermoreversible poly 
mer is described by formula ( I ) or ( II ) . 
[ 0106 ] In some embodiments of formula ( II ) , d is 0 . In 
some embodiments of formula ( II ) , a > 0 . 8 . In some embodi 
ments of formula ( II ) , 0 . 1 > b > 0 . In some embodiments of 
formula ( II ) , c < 0 . 2 . In some embodiments of formula ( II ) , 
a > 0 . 8 ; 0 . 1 > b > 0 and c < 0 . 2 . 
01071 In some embodiments of formula ( II ) , b > 0 . In some 
embodiments of formula ( II ) , b < 0 . 5 . In some embodiments 
of formula ( II ) , b < 0 . 4 . In some embodiments of formula ( II ) , 
b < 0 . 3 . In some embodiments of formula ( II ) , b < 0 . 2 . In some 
embodiments of formula ( II ) , b < 0 . 1 . In some embodiments 
of formula ( II ) , O < b < 0 . 1 . In some embodiments of formula 
( II ) , 0 < b < 0 . 05 . In some embodiments of formula ( II ) , 
O < b < 0 . 02 . 
[ 0108 ] In some embodiments of formula ( II ) , d is 0 . In 
some embodiments of formula ( II ) , d > 0 . In some embodi 
ments of formula ( II ) , d < 0 . 5 . In some embodiments of 
formula ( II ) , d < 0 . 4 . In some embodiments of formula ( II ) , 
d < 0 . 3 . In some embodiments of formula ( I ) , d < 0 . 2 . In some 
embodiments of formula ( II ) , d < 0 . 1 . In some embodiments 
of formula ( II ) , O < d < 0 . 1 . In some embodiments of formula 
( II ) , 0 < d < 0 . 05 . 
10109 ] In some embodiments of formula ( II ) , a > 0 . 3 . In 
some embodiments of formula ( II ) , a > 0 . 4 . In some embodi 
ments of formula ( II ) , a > 0 . 5 . In some embodiments of 
formula ( II ) , a > 0 . 6 . In some embodiments of formula ( II ) , 
a > 0 . 7 . In some embodiments of formula ( I ) , a > 0 . 8 . In some 
embodiments of formula ( II ) , a > 0 . 9 . 
0110 ] In some embodiments of formula ( II ) , c > 0 . 1 . In 
some embodiments of formula ( II ) , c > 0 . 2 . In some embodi 
ments of formula ( II ) , c > 0 . 3 . In some embodiments of 
formula ( I ) , c < 0 . 3 . In some embodiments of formula ( II ) , 
c < 0 . 2 . In some embodiments of formula ( I ) , O < c < 0 . 2 . In 
some embodiments of formula ( II ) , 0 < c < 0 . 15 . 
[ 0111 ] In some embodiments of formula ( II ) , a > 0 . 9 , 
O < b < 0 . 02 , 0 < c < 0 . 2 and O < d < 0 . 05 . 
10112 ] In some embodiments of formula ( II ) , R ' is a lower 
alkyl or a substituted lower alkyl . In some embodiments of 
formula ( II ) , R1 is a lower alkyl selected from the group 
consisting of methyl , ethyl , propyl , butyl , pentyl , isopropyl , 
isobutyl , isopentyl , tert - butyl , cyclopropyl , and cyclobutyl . 
In certain embodiments , R is methyl . In certain embodi 
ments , R ' is ethyl . In certain embodiments , R ' is propyl . In 
certain embodiments , R ' is butyl . In certain embodiments , 
R is pentyl . In certain embodiments , Rl is isopropyl . In 
certain embodiments , Riis isobutyl . In certain embodi 
ments , R ' is isopentyl . In certain embodiments , R ' is tert 
butyl . In certain embodiments , R1 is cyclopropyl . In certain 
embodiments , Rl is cyclobutyl . 
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ments of formula ( III ) , c < 0 . 3 . In some embodiments of 
formula ( III ) , c < 0 . 4 . In some embodiments of formula ( III ) , 
c < 0 . 5 . 
[ 0119 ] In some embodiments of formula ( III ) , PEG , is a 
polyethylglycol polymer having a MW of 3 kDa or greater , 
such as 3 kDa to 100 kDa or 3 kD to 10 kDa , such as 3400 
Da . 
[ 0120 ] In some embodiments , the thermoreversible poly 
mer comprises a polymeric segment described by formula 
( IV ) : 
( IV ) 
[ 0113 ] In some embodiments of formula ( II ) , Z2 is a 
functional group selected from an amino , a thiol , a carbox - 
ylic acid , a maleimide , a vinyl sulfone , a haloacetyl , an 
azide , an alkyne ( e . g . , a cyclooctyne ) , and protected versions 
thereof . In some embodiments of formula ( II ) , Zº is a thiol . 
In some embodiments of formula ( II ) , Z ' is an azide . In some 
embodiments of formula ( II ) , Z ? is a maleimide . In some 
embodiments of formula ( II ) , Z is a linked modifying agent 
( e . g . , as described herein ) . In certain instances of formula ( I ) 
or ( II ) , Z is a linked modifying agent selected from a 
heparin , a hyaluronic acid , a specific binding member , a 
peptide , a nucleic acid , gelatin , fibronectin , collagen , lami 
nin , basic fibroblast growth factor ( bFGF ) , epidermal growth 
factor ( EGF ) , insulin , progesterone , glucose , a stromal cell 
derived factor ( SDF ) ( e . g . , SDF - 1 ) , thymosin beta - 4 , a sonic 
hedgehog ( SHH ) polypeptide , Noggin , Activin , atransform 
ing growth factor ( TGF ) ( e . g . , TGF63 ) , a fibroblast growth 
factor ( FGF ) ( e . g . , FGF8 ) , brain - derived neurotrophic factor 
( BDNF ) , glial cell - derived neurotrophic factor ( GDNF ) , a 
neutrophin ( NT ) ( e . g . , NT3 ) , a platelet - derived growth fac 
tor ( PDGF ) ( e . g . , PDGF - AA ) , and insulin - like growth factor 
( IGF ) ( e . g . , IGF - 1 ) . In certain instances of formula ( I ) or ( II ) , 
Z2 is a linked modifying agent that is a cytokine , a bone 
morphogenetic protein ( BMP ) family member ( e . g . , TGF 
beta or activin ) , a neutrophin ( e . g . , NT3 or BDNF ) or a 
hedgehog protein ( e . g . , SHH ) . 
[ 0114 ] In some embodiments , the thermoreversible poly 
mer comprises a polymeric segment described by formula 
( III ) : 
HN OHN OOOHN o DEL PEG , NH2 heparin 
[ 0121 ] wherein G ' , G? , PEG , L and a - d are as described 
in formula ( I ) - ( III ) . In some embodiments , the thermorevers 
ible polymer is described by formula ( IV ) . 
[ 0122 ] In certain embodiments of any one of formulae ( I ) - ( IV ) , G1 and G2 are each independently selected from a 
terminal group , a linker and a linked modifying agent . 
[ 0123 ] In certain embodiments of any one of formulae ( I ) - ( IV ) , Gº , Gº and / or Z2 comprise the following structure : ( III ) 
ma oth he 
- 
HN TO HN Co US OH O 
PEG , 
NH2 O HO ?? 
OH 
wherein Gº , G? , PEG , , and a - c are as described in formulae 
( I ) and ( II ) . 
10115 ] In some embodiments of formula ( III ) , a > 0 . 8 . In 
some embodiments of formula ( III ) , a > 0 . 9 . In some embodi 
ments of formula ( III ) , 0 . 1 > b > 0 . In some embodiments of 
formula ( III ) , 0 . 02 > b > 0 . In some embodiments of formula 
( III ) , 0 . 2 > c > 0 . In some embodiments of formula ( III ) , 
0 . 15 > c > 0 . In some embodiments of formula ( III ) , a > 0 . 9 ; 
0 . 02 > b > 0 and 0 . 15 > c > 0 . In some embodiments of formula 
( III ) , a > 0 . 8 ; 0 . 1 > b > 0 and 0 . 2 > c > 0 . 
[ 0116 ] In some embodiments of formula ( III ) , b > 0 . In 
some embodiments of formula ( III ) , b < 0 . 5 . In some embodi 
ments of formula ( III ) , b < 0 . 4 . In some embodiments of 
formula ( III ) , b < 0 . 3 . In some embodiments of formula ( III ) , 
b < 0 . 2 . In some embodiments of formula ( III ) , b < 0 . 1 . 
[ 0117 ] In some embodiments of formula ( III ) , a > 0 . 3 . In 
some embodiments of formula ( III ) , a > 0 . 4 . In some embodi 
ments of formula ( III ) , a > 0 . 5 . In some embodiments of 
formula ( III ) , a > 0 . 6 . In some embodiments of formula ( III ) , 
a > 0 . 7 . 
[ 0118 ] In some embodiments of formula ( III ) , c < 0 . 1 . In 
some embodiments of formula ( III ) , c < 0 . 2 . In some embodi - 
where the brackets and “ * ” represent that the monomer 
structure depicted can be a polymeric hyaluronic acid of any 
convenient number of monomeric units ; and L is a linker . In 
certain instances , the subject thermoreversible polymers 
include a linked hyaluronic acid ( e . g . , linked via a terminal 
or a sidechain linker ) . In certain instances , conjugation to a 
linked hyaluronic acid is achieved using thiol / vinyl sulfone , 
thiol / maleimide , thiol / iodacetamide , thiol / haloacetyl or 
azide / alkyne conjugation chemistry . In certain instances , 
conjugation to a linked hyaluronic acid is achieved using 
a - halocarbonyls , Michael acceptors , B - haloethylamines , or 
any a , ß - unsaturated systems . The hyaluronic acid itself may 
include a variety of conjugation sites to a variety of poly 
mers of interest . In certain cases , the hyaluronic acid itself 
includes a plurality of linkages to one or more moieties of 
interest , including one or more of the subject thermorevers 
ible polymers . In certain instances , the thermoreversible 
polymer includes multiple linkages to a hyaluronic acid of 
interest . 
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[ 0124 ] The linked hyaluronic acid can be of any conve 
nient molecular weight . In some embodiments , the linked 
hyaluronic acid itself has a MW of 100 kDa or more , such 
as 200 kDa or more , 300 kDa or more , 400 kDa or more , 500 
kDa or more , 600 kDa or more , 700 kDa or more , 800 kDa 
or more , 900 kDa or more , 1 MDa or more , or even more . 
In some embodiments , the linked hyaluronic acid itself has 
a MW of 100 kDa to 1 MDa , such as 200 kDa to 1 MDa , 300 
kDa to 1 MDa , 400 kDa to 1 MDa , or 500 kDa to 1 MDa . 
[ 0125 ] In certain instances , the ratio of hyaluronic acid to 
thermoreversible polymer in the resulting conjugate struc 
ture may be in the range of 1 : 10 to 1 : 1 . 25 by weight , such 
as about 1 : 10 , about 1 : 5 , about 1 : 2 . 5 or about 1 : 1 . 25 . [ 0126 ] In certain embodiments of formulae ( 1 ) - ( II ) , Z2 
comprises the following structure : 
HO 
OH ?? 
has a MW in the range or 50 kDa to 300 kDa , such as 50 kDa 
to 250 kDa , 50 kDa to 200 kDa , 50 kDa to 150 kDa , or 50 
kDa to 100 kDa . In certain embodiments , the thermorevers 
ible polymer has a MW of 5 kDa or more . In certain 
embodiments , the thermoreversible polymer has a MW of 5 
kDa to 500 kDa . 
10129 ] . In some embodiments , the thermoreversible poly 
mer has a loss modulus when in solid or gel form of 100 Pa 
or more , such as 200 Pa or more , 300 Pa or more , 400 Pa or 
more , 500 Pa or more , 600 Pa or more , 700 Pa or more , 800 
Pa or more , 900 Pa or more , 1000 Pa or more , 2000 Pa or 
more , 3000 Pa or more , 4000 Pa or more , 5000 Pa or more , 
or even more . In certain instances , the loss modulus is 
measured at 37° C . 
[ 0130 ] In some embodiments , the thermoreversible poly 
mer has a storage modulus when in solid or gel form of 50 
Pa or more , 100 Pa or more , such as 200 Pa or more , 300 Pa 
or more , 400 Pa or more , 500 Pa or more , 600 Pa or more , 
700 Pa or more , 800 Pa or more , 900 Pa or more , 1000 Pa 
or more , 2000 Pa or more , 3000 Pa or more , 4000 Pa or 
more , 5000 Pa or more , or even more . In certain instances , 
the storage modulus is measured at 37° C . In certain 
instances , increasing the molecular weight of hyaluronic 
acid increases the storage modulus of the thermoreversible 
polymer . In certain instances , increasing the molecular 
weight of PEG for copolymers containing isobutyl meth 
acrylate and butyl methacrylate increases the storage modu 
lus of the thermoreversible polymer . In certain instances , 
increasing the polymer concentration increases the storage 
modulus of the thermoreversible polymer . In certain 
instances , increasing the alkyl chain of between methyl , 
ethyl , and isobutyl methacrylate increases the storage modu 
lus of the thermoreversible polymer . [ 0131 ] Compositions 
10132 ] The present disclosure provides a composition 
including two or more thermoreversible polymers of the 
present disclosure . In some embodiments , the composition 
includes a mixture of a low MW thermoreversible polymer 
( e . g . , having a MW of 100 kDa or less , such as 75 kDa or 
less , or 50 kDa or less ) and a high MW thermoreversible 
polymer ( e . g . , having a MW of 100 kDa or more , such as 
200 kDa or more , 300 kDa or more , 500 kDa or more , or 
even more ) . 
[ 0133 ] Aspects of the present disclosure include a hydro 
gel composition including a thermoreversible polymer and 
an aqueous solution . When the hydrogel composition is 
below its sol - gel transition temperature , the composition can 
be a homogeneous solution , such that any cells that are 
present in the solution may be easily removed ( e . g . , by 
centrifugation ) . When the hydrogel composition is above its 
sol - gel transition temperature , the thermoreversible polymer 
provides a three - dimensional matrix that finds use in the 
incubation , growth and / or differentiation of cells of interest . 
0134 ] Any convenient buffered aqueous solutions that 
find use in the incubation and / or differentiation of cells of 
interest may be utilized in the subject hydrogel composi 
tions . The buffered aqueous solution may include any con 
venient components of interest . 
10135 ] In some instances , the hydrogel composition fur 
ther includes cells of interest ( e . g . , as described herein ) . In 
certain embodiments , the hydrogel composition includes 
stem cells selected from the group consisting of ( a ) adult 
stem cell derived from bone marrow , umbilical tissues , or 
placenta ; ( b ) neural stem cell ; and ( c ) embryonic stem cell . 
[ 0127 ] In certain embodiments of formulae ( 1 ) - ( IV ) , G1 
and / or G? comprise the following structure : 
non 
OH NH 
[ 0128 ] The subject thermoreversible polymers may have 
any convenient MW . In certain embodiments , the thermor 
eversible polymer has a MW of 500 kDa or less , such as 400 
kDa or less , 300 kDa or less , 250 kDa or less , 200 kDa or 
less , 150 kDa or less , 100 kDa or less , 90 kDa or less , 80 kDa 
or less , 70 kDa or less , 60 kDa or less , or even 50 kDa or 
less . In certain embodiments , the thermoreversible polymer 
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polymer - cell composition of the present disclosure can be 
implanted into an individual in need thereof , where cells 
proliferate and / or differentiated within the implanted ther 
moreversible polymer - cell composition , and migrate out of 
the implanted thermoreversible polymer - cell composition . 
[ 0136 ] In certain instances , the thermoreversible polymer 
is a solid , semi - solid , or gel at 20° C . or more , such as 21° 
C . or more , 22° C . or more , 23° C . or more , 24° C . or more , 
25° C . or more , 26° C . or more , 27° C . or more , 28° C . or 
more , 29° C . or more , 30° C . or more , 31° C . or more , 32° 
C . or more , 33° C . or more , 34° C . or more , 35° C . or more , 
36° C . or more , or even more . In certain embodiments , the 
thermoreversible polymer is a solid at 37° C . 
10137 ] In certain instances , the thermoreversible polymer 
( e . g . , a thermoreversible polymer of Formula 1 , Formula II , 
Formula III , or Formula IV ) is a solid , semi - solid , or gel at 
10° C . or more , or 15° or more . In certain instances , the 
thermoreversible polymer ( e . g . , a thermoreversible polymer 
of Formula 1 , Formula II , Formula III , or Formula IV ) is a 
solid , semi - solid , or gel at a temperature of from 10° C . to 
15° C . , from 15° C . to 20° C . , or 20° C . to 25° C . In some 
cases , the thermoreversible polymer ( e . g . , a thermorevers 
ible polymer of Formula I , Formula II , Formula III , or 
Formula IV ) is a solid , semi - solid , or gel at a temperature of 
from 10° C . to 15º C . 
[ 0138 ] In some embodiments , the thermoreversible poly 
mer is a liquid at 30° C . or less , such as 25° C . or less , 200 
C . or less , 18° C . or less , 16° C . or less , 14° C . or less , 12° 
C . or less , 10° C . or less , 8° C . or less , 6° C . or less , or 4° 
C . or less . In certain embodiments , the thermoreversible 
polymer is a liquid at less than 20° C . In certain embodi 
ments , the thermoreversible polymer is a liquid at 4° C . 
[ 0139 ] In some cases , a thermoreversible polymer ( e . g . , a 
thermoreversible polymer of Formula I , Formula II , Formula 
III , or Formula IV ) has a sol - gel transition temperature or 
LCST in the range of 5 - 35° C . , such as 10 - 35° C . , 10 - 30° C . , 
10 - 25° C . or 10 - 20° C . In some cases , a thermoreversible 
polymer ( e . g . , a thermoreversible polymer of Formula I , 
Formula II , Formula III , or Formula IV ) has an LCST in the 
range of 10° C . to about 15° C . [ 0140 ] The subject thermoreversible polymers can be pre 
pared using any convenient methods . A variety of polym 
erization methods may be utilized in preparing a base 
polymeric material , e . g . , including polyacrylate , polyacryl 
amide and mixtures thereof . A variety of derivatization 
methods may be utilized to introduce any convenient func 
tionality into the subject base polymeric materials . A variety 
of chemoselective conjugation chemistries , linkers , func 
tional groups and modifying agents may be utilized in the 
preparation of further derivatives and conjugates of the 
subject base polymeric materials and derivatives thereof . 
For example , any of the methods depicted in FIG . 3 , FIG . 9 , 
FIG . 10 , FIG . 12 , FIG . 13 , FIG . 14 , FIG . 16 and FIG . 19 may 
be adapted for use in preparing the subject thermoreversible 
polymers . 
Methods for Culturing Cells 
[ 0142 ] A thermoreversible polymer of the present disclo 
sure can be used to culture cells in vitro or in vivo . Thus , the 
present disclosure provides methods of culturing cells , the 
methods involving contacting the cells with the thermor 
eversible polymer ; and culturing the cell - containing ther 
moreversible polymer under conditions suitable for growth 
and / or differentiation of the cells . In some cases , a method 
of the present disclosure comprises culturing cells contained 
within ( e . g . , embedded in ; suspended in ; etc . ) a hydrogel 
composition of the present disclosure . 
[ 0143 ] In some cases , a method of the present disclosure 
for culturing cells comprises culturing the cells in a hydrogel 
composition of the present disclosure at a temperature ( e . g . , 
from about 30° C . to about 37° C . ; e . g . , at 37° C . ) at which 
the hydrogel composition is a semi - solid ( e . g . , a gel ) . In 
some cases , a method of the present disclosure for culturing 
cells comprises culturing the cells in a hydrogel composition 
of the present disclosure at a temperature ( e . g . , from about 
4° C . to about 10° C . ; e . g . , at 4° C . ) at which the hydrogel 
composition is a liquid . 
10144 ] A method of the present disclosure for culturing 
cells can be used to generate a desired number of cells , 
including differentiated cells and stem cells . For example , a 
method of the present disclosure can be used to generate 
from 102 cells to about 10 cells , e . g . , from about 102 cells 
to about 5x10 ' cells , from about 5x10 cells to about 10 
cells , from about 103 cells to about 5x103 cells , from about 
5x10 ' cells to about 104 cells , from about 104 cells to about 
5x104 cells , from about 5x104 cells to about 109 cells , from 
about 10 cells to about 5x10 cells , from about 5x10 cells 
to about 10 cells , from about 10 cells to about 5x10 cells , 
from about 5x100 cells to about 107 cells , from about 107 
cells to about 5x10 ' cells , from about 5x10 ' cells to about 
108 cells , from about 10 cells to about 5x108 cells , or from 
about 5x108 cells to about 10 % cells . In some cases , a method 
of the present disclosure can be used to generate more than 
109 cells , e . g . , from 10 % cells to 5x10 ' cells , from 5x10 cells 
to 1010 cells , from 1010 cells to 5x1010 cells , from 5x1010 
cells to 1011 cells , from 1011 cells to 5x1011 cells , from 
5x1011 cells to 1012 cells , from 1012 cells to 5x1012 cells , 
from 5x1012 cells to 1012 cells , from 1012 cells to 5x1013 
cells , from 5x1013 cells to 1014 cells , from 1014 cells to 
5x1014 cells , or from 5x1014 cells to 10ls cells . [ 0145 ] Cells can be cultured in a hydrogel composition of 
the present disclosure can be present in the hydrogel com 
position ( e . g . , embedded within the hydrogel composition ; 
suspended in the hydrogel composition ; etc . ) at a density of 
from 10 cells per mL ( or cubic centimeters ) hydrogel to 
about 108 cells per mL , e . g . , from about 10 cells per mL to 
about 102 cells per mL , from about 102 cells per mL to about 
104 cells per mL , from about 104 cells per mL to about 106 
cells per mL , or from about 10° cells per mL to about 108 
cells per mL . 
[ 0146 ] In some cases , the hydrogel composition maintains 
pluripotency of pluripotent stem cells contained within the 
hydrogel composition . For example , in some cases , the 
hydrogel composition maintains pluripotency of pluripotent 
Thermoreversible Polymer - Cell Compositions 
[ 0141 ] The present disclosure provides a composition 
comprising : a ) a thermoreversible polymer of the present 
disclosure ; and b ) cells embedded or suspended within the 
polymer . A thermoreversible polymer - cell composition of 
the present disclosure is useful for generating a desired 
number of cells , by culturing the thermoreversible polymer - 
cell composition under conditions and for a period of time 
sufficient to generate the desired number of cells . Such cells 
can include stem cells , differentiated cells , and the like . A 
thermoreversible polymer - cell composition of the present 
disclosure is useful for differentiating cells , e . g . , to generate 
a desired number of differentiated cells . A thermoreversible 
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stem cells contained within the hydrogel composition when 
cultured in the hydrogel composition for a period of time of 
1 day to 6 months or more . For example , in some cases , the 
hydrogel composition maintains pluripotency of pluripotent 
stem cells contained within the hydrogel composition when 
cultured in the hydrogel composition for a period of time of 
1 day to 7 days , from 1 week to 2 weeks , from 2 weeks to 
one month , from one month to 2 months , from 2 months to 
4 months , or from 4 months to 6 months . For example , in 
some cases , the hydrogel composition maintains pluripo 
tency of at least 10 % , at least 20 % , at least 30 % , at least 
40 % , at least 50 % , at least 60 % , at least 70 % , at least 80 % , 
at least 90 % , or more than 90 % , of the pluripotent stem cells 
contained within the hydrogel composition when cultured in 
the hydrogel composition for a period of time of 1 day to 7 
days , from 1 week to 2 weeks , from 2 weeks to one month , 
from one month to 2 months , from 2 months to 4 months , or 
from 4 months to 6 months . In some cases , the hydrogel 
composition provides sufficient time for cell propagation . In 
some cases , the cells cultured in the hydrogel composition 
maintain pluripotency after 1 passage , after 2 passages , after 
3 passages or after more than 3 passages . In some cases , the 
hydrogel composition maintains pluripotency of human 
pluripotent stem cells ( hPSCS ) . In some cases , the hPSCs are 
Hi embryonic stem cells ( H1ESCs ) . In some cases , the 
hPSCs are H9 embryonic stem cells ( HGESCs ) . In some 
cases , the hydrogel composition maintains pluripotency of 
induced pluripotent stem cells ( iPSCs ) . In some cases , the 
iPSCs cultured in the hydrogel maintain pluripotency after 1 
passage , after 2 passages , after 3 passages , or after more than 
3 passages ( e . g . , after 4 passages , after 5 passages , after from 
5 to 10 passages , after from 10 to 15 passages , after from 15 
to 20 passages , etc . ) . 
[ 0147 ] In some cases , cells cultured in the hydrogel com 
position aggregate . For example , in some cases , the cells 
cultured in the hydrogel composition grow as small aggre 
gates after 1 day in culture . In some cases , cells cultured in 
the hydrogel composition grow as single cells at 1 day in 
culture . In some cases , the cells cultured in the hydrogel 
composition aggregate after 2 days in culture . In some cases , 
cells cultured in the hydrogel composition aggregate after 3 
days in culture . In some cases , cells cultured in the hydrogel 
composition aggregate after 4 days in culture . In some 
instances , the cells are H9ESCs . In some cases , H9ESCs 
grow as small aggregates at 1 day in culture . In some 
instances , H9ESCs grow as large aggregates at 4 days in 
culture . 
[ 0148 ] The hydrogel composition can include one or more 
factors ( e . g . , polypeptides ; small molecules ; etc . ) that pro 
mote proliferation or differentiation of cells cultured in the 
hydrogel composition . Suitable factors include , e . g . , retinoic 
acid , a Wnt agonist , an Shh signaling pathway agonist , a 
bone morphogenic protein ( BMP ) inhibitor ( e . g . , Noggin ) , a 
receptor tyrosine kinase ligand ( e . g . , epidermal growth fac 
tor ) , nicotinamide , a p38 inhibitor , a dual - Smad inhibitor , a 
Rock inhibitor , gastrin , an activator of the prostaglanding 
signalling pathway , fibroblast growth factor ( FGF ) ( e . g . , 
FGF10 ) , a TGF - B inhibitor , Rspondin , an Rspondin mimic , 
and combinations of two or more of the aforementioned 
factors . Such factors can be present in the hydrogel com 
position at concentrations ranging from 1 nM to 100 mm , 
e . g . , from 1 nM to 50 nM , from 50 nM to 100 nM , from 100 
nM to 0 . 5 °M , from 0 . 5 uM to 1 uM , from 1 uM to 50 uM , 
from 50 uM to 100 uM , from 100 uM to 0 . 5 mM , from 0 . 5 
uM to 1 mM , from 1 mM to 50 mM , or from 50 mM to 100 
mM . Such factors can be present in the hydrogel composi 
tion at concentrations ranging from 1 ng / ml to 1 mg / ml , e . g . , 
from 1 ng / ml to 50 ng / ml , from 50 ng / ml to 100 ng / ml , from 
100 ng / ml to 0 . 5 ug / ml , from 0 . 5 ug / ml to 1 ug / ml , from 1 
ug / ml to 50 ug / ml , from 50 ug / ml to 100 ug / ml , from 100 
ug / ml to 500 ug / ml , from 500 ug / ml to 0 . 1 mg / ml , from 0 . 1 
mg / ml to 0 . 5 mg / ml , or from 0 . 5 mg / ml to 1 mg / ml , or more 
than 1 mg / ml . 
[ 0149 ] In some cases , a hydrogel composition of the 
present disclosure includes one or more of : Rspondin 1 - 4 
and / or an Rspondin mimic , a BMP inhibitor ( for example , 
Noggin ) , a TGF - beta inhibitor , a receptor tyrosine kinase 
ligand ( for example , EGF ) , Nicotinamide , a Wnt agonist ( for 
example , Wnt ( 3a ) ) , a Wnt antagonist ( e . g . , IWP - 2 , IWP - 3 , 
IWP - 4 , Dkk1 , and the like ) , a p38 inhibitor , gastrin , FGF10 , 
HGF and a ROCK inhibitor . 
[ 0150 ] Several classes of natural BMP - binding proteins 
are known , including Noggin , Chordin and chordin - like 
proteins comprising chordin domains , Follistatin and fol 
listatin - related proteins comprising a follistatin domain , 
DAN and DAN - like proteins comprising a DAN cysteine 
knot domain , sclerostin / SOST ( R & D systems ) and apha - 2 
macroglobulin . A BMP inhibitor is an agent that binds to a 
BMP molecule to form a complex wherein the BMP activity 
is reduced , for example by preventing or inhibiting the 
binding of the BMP molecule to a BMP receptor . Alterna 
tively , the inhibitor may be an agent that binds to a BMP 
receptor and prevents binding of a BMP ligand to the 
receptor , for example , an antibody that binds the receptor . A 
BMP inhibitor may be a protein or small molecule and may 
be naturally occurring , modified , and / or partially or entirely 
synthetic . A BMP inhibitor can be Noggin , DAN , or DAN 
like proteins including Cerberus and Gremlin . In some 
cases , the BMP inhibitor is Noggin . The BMP inhibitor ( e . g . , 
Noggin ) may be used at any suitable concentration . A 
hydrogel composition of the present disclosure can include 
Noggin in a concentration of between about 10 ng / ml and 
about 100 ng / ml of Noggin . 
[ 0151 ] A hydrogel composition of the present disclosure 
can include one or more Wnt agonists . The Wnt signalling 
pathway is defined by a series of events that occur when a 
Wnt protein binds to a cell - surface receptor of a Frizzled 
receptor family member . This results in the activation of 
Dishevelled family proteins which inhibit a complex of 
proteins that includes axin , GSK - 3 , and the protein APC to 
degrade intracellular beta - catenin . The resulting enriched 
nuclear beta - catenin enhances transcription by TCF / LEF 
family transcription factors . A Wnt agonist is defined as an 
agent that activates TCF / LEF - mediated transcription in a 
cell . Wnt agonists can be Wnt agonists that bind and activate 
a Frizzled receptor family member including any and all of 
the Wnt family proteins , an inhibitor of intracellular beta 
catenin degradation , and activators of TCF / LEF . 
[ 0152 ] Suitable Wnt agonists include a secreted glycopro 
tein including Wnt - 1 / Int - 1 , Wnt - 2 / Irp ( InM - related Protein ) , 
Wnt - 2b / 13 , Wnt - 3 / Int - 4 , Wnt - 3a , Wnt - 4 , Wnt - 5a , Wnt - 5b , 
Wnt - 6 , Writ - 7a , Wnt - 7b , Wnt - 8a / 8d , Wnt - 8b , Wnt - 9a / 14 , 
Wnt - 9b / 14b / 15 , Wnt - 10a , Wnt - 10b / 12 , WnM 1 , and Wnt 
16 . Other suitable Wnt agonists include the R - spondin 
family of secreted proteins , which is implicated in the 
activation and regulation of Wnt signaling pathway and 
which is comprised of 4 members ( R - spondin 1 , R - spondin 
2 , R - spondin 3 , and R - spondin - 4 ) , and Norrin ( also called 
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Nome Disease Protein or NDP ) , which is a secreted regu - 
latory protein that functions like a Wnt protein in that it 
binds with high affinity to the Frizzled - 4 receptor and 
induces activation of the Wnt signaling pathway . Also 
suitable is an R - spondin mimic , for example an agonist of 
Lgr5 such as an anti - Lgr5 antibody . 
[ 0153 ] Suitable Wnt agonists include a GSK - inhibitor . 
Known GSK - inhibitors comprise small - interfering RNAs 
( siRNA ) , lithium , kenpaullone , 6 - Bromoindirubin - 30 - ac 
etoxime , SB 216763 and SB 415286 , and FRAT - family 
members and FRAT - derived peptides that prevent interac 
tion of GSK - 3 with axin . 
[ 0154 ] Suitable Wnt agonists include Wnt - 3a , a GSK 
inhibitor ( such as CHIR99021 ) , Wnt 5 , Wnt - 6a , Norrin , and 
any other Wnt family protein . 
[ 0155 ] A Wnt agonist can be included in the hydrogel 
composition in a suitable concentration . For example , 
CHIR99021 ( 6 - [ [ 2 - [ [ 4 - ( 2 , 4 - Dichlorophenyl ) - 5 - ( 5 - methyl 
1H - imidazol - 2 - yl ) - 2 - pyrimidinyl ] amino ) ethyl?amino ] - 3 
pyridinecarbonitrile ) can be included in a final concentration 
of between 50 nM and 100 uM , for example between 100 
nM and 50 uM , between 1 uM and 10 uM , between 1 uM 
and 5 uM , or 3 uM . 
[ 0156 ] A hydrogel composition of the present disclosure 
can comprise one or more receptor tyrosine kinase ligands . 
An example of a suitable receptor tyrosine kinase ligand is 
EGF , which is the ligand for the receptor tyrosine kinase 
EGFR . Many receptor tyrosine kinase ligands are also 
mitogenic growth factors . 
[ 0157 ] A hydrogel composition of the present disclosure 
can include a TGF - 1 inhibitor . Examples of suitable TGF - 1 
inhibitors include , e . g . , 3 - ( 6 - methyl - 2 - pyridinyl ) - N - phenyl 
4 - ( 4 - quinolinyl ) - 1H - pyrazole - 1 - carbothioamide ( A83 - 01 ) ; 
4 - [ 4 - ( 1 , 3 - benzodioxol - 5 - yl ) - 5 - ( 2 - pyridinyl ) - 1H - imidazol 
2 - yl ] benzamide ( SB - 431542 ) ; and the like . Suitable TGF - 1 
inhibitors include those listed in Table 1 of U . S . Patent 
Publication No . 2014 / 0243227 ; for example , A83 - 01 , 
SB - 431542 , SB - 505124 , SB - 525334 , SD - 208 , LY - 36494 
and SJN - 2511 . 
[ 0158 ] A hydrogel composition of the present disclosure 
can comprise one or more mitogenic growth factor . The one 
or more mitogenic growth factor may be selected from a 
family of growth factors comprising epidermal growth fac 
tor ( EGF ) , Transforming Growth Factor - alpha ( TGF - alpha ) , 
basic Fibroblast Growth Factor ( bFGF ) , brain - derived neu 
rotrophic factor ( BDNF ) , and Keratinocyte Growth Factor 
( KGF ) . 
[ 0159 ] A hydrogel composition of the present disclosure 
can include a Rock ( Rho - kinase ) inhibitor . Suitable Rock 
inhibitors include , e . g . , R - ( + ) - trans - 4 - ( 1 - aminoethyl ) - N - ( 4 
Pyridyl ) cyclohexanecarboxamide dihydrochloride monohy 
drate ( Y - 27632 , Sigma - Aldrich ) , 5 - ( 1 , 4 - diazepan - 1 - ylsulfo 
nyl ) isoquinoline ( fasudil or HA1077 , Cayman Chemical ) , 
and ( S ) - ( + ) - 2 - methyl - 1 - [ ( 4 - methyl - 5 - isoquinolinyl ) sulfo 
nyl ] - hexahydro - 1H - 1 , 4 - diazepine dihydrochloride ( H - 1 
152 , Tocris Bioschience ) . [ 0160 ] A hydrogel composition of the present disclosure 
can include a Notch agonist . Examples of suitable Notch 
agonists include Jagged 1 and Delta 1 , or an active fragment 
or derivative thereof . A suitable Notch agonist is a DSL 
peptide ( Dontu et al . , 2004 . Breast Cancer Res 6 . R605 
R615 ) with the sequence CDDYYYGFGCNKFCRPR ( SEQ 
ID NO : 1 ) . 
?0161 ] A hydrogel composition of the present disclosure 
can include an activator of the prostaglandin signalling 
pathway Such activators include , e . g . , Phospholipids , 
Arachidonic acid ( AA ) , prostaglandin E2 ( PGE2 ) , prosta 
glandin G2 ( PGG2 ) , prostaglandin F2 ( PGF2 ) , prostaglan 
din H2 ( PGH2 ) , and prostaglandin D2 ( PGD2 ) . 
[ 0162 ] A hydrogel composition of the present disclosure 
can include a RANK ligand . [ 0163 ] The pH of a hydrogel composition of the present 
disclosure can be in the range from about 7 . 0 to 7 . 8 , in the 
range from about 7 . 2 to 7 . 6 , or about 7 . 4 . The pH may be 
maintained using a buffer . A suitable buffer can readily be 
selected by the skilled person . Buffers that may be used 
include carbonate buffers ( e . g . NaHCO ) , and phosphates 
( e . g . NaH2PO4 ) . Other buffers such as N - [ 2 - hydroxyethyl ] 
piperazine - N - [ 2 - ethanesul - phonic acid ] ( HEPES ) and 3 - [ N 
morpholino ] - propanesulfonic acid ( MOPS ) may also be 
used . [ 0164 ] A hydrogel composition of the present disclosure 
one or more amino acids . Amino acids which may be present 
include L - alanine , L - arginine , L - asparagine , L - aspartic acid , 
L - cysteine , L - cystine , L - glutamic acid , L - glutamine , L - gly 
cine , L - histidine , L - isoleucine , L - leucine , L - lysine , L - me 
thionine , L - phenylalanine , L - proline , L - serine , L - threonine , 
L - tryptophan , L - tyrosine , L - valine and combinations 
thereof . 
[ 0165 ] A hydrogel composition of the present disclosure 
can include one or more vitamins . Vitamins which may be 
present include thiamine ( vitamin B1 ) , riboflavin ( vitamin 
B2 ) , niacin ( vitamin B3 ) , D - calcium pantothenate ( vitamin 
B5 ) , pyridoxal / pyridoxamine / pyridoxine ( vitamin B6 ) , folic 
acid ( vitamin B9 ) , cyanocobalamin ( vitamin B12 ) , ascorbic 
acid ( vitamin C ) , calciferol ( vitamin D2 ) , DL - alpha tocoph 
erol ( vitamin E ) , biotin ( vitamin H ) and menadione ( vitamin 
K ) . 
[ 0166 ] A hydrogel composition of the present disclosure 
can include one or more inorganic salts . Inorganic salts that 
may be present include salts of calcium , copper , iron , 
magnesium , potassium , sodium , zinc . The salts are normally 
used in the form of chlorides , phosphates , sulfates , nitrates 
and bicarbonates . 
[ 0167 ] In some cases , a hydrogel composition of the 
present disclosure does not include serum , e . g . , the hydrogel 
composition is serum free . In some cases , a hydrogel com 
position of the present disclosure includes a serum replace 
ment . 
[ 0168 ] hydrogel composition of the present disclosure 
can include other components . A hydrogel composition of 
the present disclosure can include standard culture medium 
components , such as amino acids , vitamins , inorganic salts , 
a carbon energy source , and a buffer . Other standard cell 
culture components that may be included in the culture 
include hormones , such as progesterone , proteins , such as 
albumin , catalase , insulin , and transferrin . [ 0169 ] A hydrogel composition of the present disclosure 
can include known cell culture media . The skilled person 
will understand from common general knowledge the types 
of culture media that might be used for cell culture , includ 
ing stem cell culture . Suitable cell culture media are avail 
able commercially , and include , but are not limited to , 
Dulbecco ' s Modified Eagle Media ( DMEM ) , Minimal 
Essential Medium ( MEM ) , Knockout - DMEM ( KO 
DMEM ) , Glasgow Minimal Essential Medium ( G - MEM ) , 
Basal Medium Eagle ( BME ) , DMEM / Ham ' s F12 , 
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Advanced DMEM / Ham ' s F12 , Iscove ' s Modified Dulbec - 
co ' s Media and Minimal Essential Media ( MEM ) , Ham ' s 
F - 10 , Ham ' s F - 12 , Medium 199 , and RPMI 1640 Media . 
[ 0170 ) Cells that can be cultured using a method of the 
present disclosure include mammalian cells . The cells can be 
undifferentiated cells , such as pluripotent , multipotent , oli 
gopotent or unipotent cells . The cells can be differentiated 
cells . The cells can be a mix of differentiated and undiffer 
entiated cells . The cells being cultured in a hydrogel com 
position of the present disclosure can be a single type of cell ; 
or can be a mixture of two or more types of cells . 
[ 0171 ] The cells can be primary cells , genetically modified 
cells ( e . g . , genetically modified primary cells ) , and the like . 
The cells can be human cells , non - human primate cells , 
rodent ( e . g . , mouse ; rat ) cells , lagomorph ( e . g . , rabbit ) cells , 
ungulate cells , etc . Cells of any of a variety of cell types can 
be cultured using a method of the present disclosure . Such 
cells can include cells from tissue samples , including but not 
limited to , blood , bone , brain , kidney , muscle , spinal cord , 
nerve , endocrine system , uterine , ear , foreskin , liver , intes 
tine , bladder or skin . The cells can be obtained from an 
individual having a particular disease or an individual in 
need of pluripotent stem cells . The cells can include neural 
cells , lymphocytes , epidermal cells , intestinal cells , fibro 
blasts , keratinocytes , adipocytes , cardiomyocytes , pancre 
atic islet cells , hepatocytes , astrocytes , oligodendrocytes , 
retinal cells , and the like . The cells can be autologous cells ; 
for example , the cells can be obtained from an individual , 
and cultured using a method of the present disclosure , 
whereupon , after culturing ( and possible modification , dif 
ferentiation , etc . ) , returned to the individual from which the 
cells were obtained . In some cases , the cells are human cells . 
In some cases , the cells are rodent ( e . g . , mouse ; rat ) cells . In 
some cases , the cells are non - human primate cells . 
[ 0172 ] Cells that can be cultured using a method of the 
present disclosure include hematopoietic stem cells , embry 
onic stem cells , mesenchymal stem cells , neural stem cells , 
epidermal stem cells , endothelial stem cells , gastrointestinal 
stem cells , liver stem cells , cord blood stem cells , amniotic 
fluid stem cells , skeletal muscle stem cells , smooth muscle 
stem cells ( e . g . , cardiac smooth muscle stem cells ) , pancre 
atic stem cells , olfactory stem cells , hematopoietic stem 
cells , induced pluripotent stem cells ; and the like 
[ 0173 ] In some cases , cells cultured using a method of the 
present disclosure are stem cells . In some cases , cells 
cultured using a method of the present disclosure are pluri 
potent stem cells . 
[ 0174 ] Suitable human embryonic stem ( ES ) cells include , 
but are not limited to , any of a variety of available human ES 
lines , e . g . , BG01 ( hESBGN - 01 ) , BG02 ( hESBGN - 02 ) , 
BG03 ( HESBGN - 03 ) ( BresaGen , Inc . ; Athens , Ga . ) ; SA01 
( Sahlgrenska 1 ) , SA02 ( Sahlgrenska 2 ) ( Cellartis AB ; 
Goeteborg , Sweden ) ; ES01 ( HES - 1 ) , ES01 ( HES - 2 ) , ESO3 ( HES - 3 ) , ES04 ( HES - 4 ) , ES05 ( HES - 5 ) , ES06 ( HES - 6 ) ( ES 
Cell International , Singapore ) ; UC01 ( HSF - 1 ) , UC06 ( HSF 
6 ) ( University of California , San Francisco ; San Francisco , 
Calif . ) ; WA01 ( H1 ) , WA07 ( H7 ) , WA09 ( H9 ) , WA13 ( H13 ) , 
WA14 ( H14 ) ( Wisconsin Alumni Research Foundation ; 
WARF ; Madison , Wis . ) . Cell line designations are given as 
the National Institutes of Health ( NIH ) code , followed in 
parentheses by the provider code . See , e . g . , U . S . Pat . No . 
6 , 875 , 607 . Suitable human ES cell lines can be positive for 
one , two , three , four , five , six , or all seven of the following 
markers : stage - specific embryonic antigen - 3 ( SSEA - 3 ) ; 
SSEA - 4 ; TRA 1 - 60 ; TRA 1 - 81 ; Oct - 4 ; GCTM - 2 ; and alka 
line phosphatase . 
[ 0175 ] Hematopoietic stem cells ( HSCs ) are mesoderm 
derived cells that can be isolated from bone marrow , blood , 
cord blood , fetal liver and yolk sac . HSCs are characterized 
as CD34 + and CD3 . HSCs can repopulate the erythroid , 
neutrophil - macrophage , megakaryocyte and lymphoid 
hematopoietic cell lineages in vivo . In vitro , HSCs can be 
induced to undergo at least some self - renewing cell divi 
sions and can be induced to differentiate to the same lineages 
as is seen in vivo . As such , HSCs can be induced to 
differentiate into one or more of erythroid cells , megakaryo 
cytes , neutrophils , macrophages , and lymphoid cells . 
[ 0176 ] Neural stem cells ( NSCs ) are capable of differen 
tiating into neurons , and glia ( including oligodendrocytes , 
and astrocytes ) . A neural stem cell is a multipotent stem cell 
which is capable of multiple divisions , and under specific 
conditions can produce daughter cells which are neural stem 
cells , or neural progenitor cells that can be neuroblasts or 
glioblasts , e . g . , cells committed to become one or more 
types of neurons and glial cells respectively . Methods of 
obtaining NSCs are known in the art . In some cases , NSCs 
cultured in the hydrogel composition remain multipotent 
after multiple passages . 
[ 0177 ] Mesenchymal stem cells ( MSC ) , originally derived 
from the embryonal mesoderm and isolated from adult bone 
marrow , can differentiate to form muscle , bone , cartilage , 
fat , marrow stroma , and tendon . Methods of isolating MSC 
are known in the art ; and any known method can be used to 
obtain MSC . See , e . g . , U . S . Pat . No . 5 , 736 , 396 , which 
describes isolation of human MSC . 
[ 0178 ] An induced pluripotent stem ( iPS ) cell is a pluri 
potent stem cell induced from a somatic cell , e . g . , a differ 
entiated somatic cell . iPS cells are capable of self - renewal 
and differentiation into cell fate - committed stem cells , 
including neural stem cells , as well as various types of 
mature cells . 
10179 iPS cells can be generated from somatic cells , 
including skin fibroblasts , using , e . g . , known methods . iPS 
cells produce and express on their cell surface one or more 
of the following cell surface antigens : SSEA - 3 , SSEA - 4 , 
TRA - 1 - 60 , TRA - 1 - 81 , TRA - 2 - 49 / 6E , and Nanog . In some 
embodiments , iPS cells produce and express on their cell 
surface SSEA - 3 , SSEA - 4 , TRA - 1 - 60 , TRA - 1 - 81 , TRA - 2 
49 / 6E , and Nanog . iPS cells express one or more of the 
following genes : Oct - 3 / 4 , Sox2 , Nanog , GDF3 , REX1 , 
FGF4 , ESG1 , DPPA2 , DPPA4 , and h?ERT . In some 
embodiments , an iPS cell expresses Oct - 3 / 4 , Sox2 , Nanog , 
GDF3 , REX1 , FGF4 , ESG1 , DPPA2 , DPPA4 , and h?ERT . 
Methods of generating iPS are known in the art , and any 
such method can be used to generate iPS . See , e . g . , Taka 
hashi and Yamanaka ( 2006 ) Cell 126 : 663 - 676 ; Yamanaka et . 
al . ( 2007 ) Nature 448 : 313 - 7 ; Wernig et al . ( 2007 ) Nature 
448 : 318 - 24 ; Maherali ( 2007 ) Cell Stem Cell 1 : 55 - 70 ; Naka 
gawa et al . ( 2008 ) Nat . Biotechnol . 26 : 101 ; Takahashi et al . 
( 2007 ) Cell 131 : 861 ; Takahashi et al . ( 2007 ) Nat . Protoc . 
2 : 3081 ; and Okita et al . ( 2007 Nature 448 : 313 . 
[ 0180 ] iPS cells can be generated from somatic cells ( e . g . , 
skin fibroblasts ) by genetically modifying the somatic cells 
with one or more expression constructs encoding Oct - 3 / 4 
and Sox2 . In some embodiments , somatic cells are geneti 
c ally modified with one or more expression constructs 
comprising nucleotide sequences encoding Oct - 3 / 4 , Sox2 , 
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Treatment Methods c - myc , and K1f4 . In some embodiments , somatic cells are 
genetically modified with one or more expression constructs 
comprising nucleotide sequences encoding Oct - 4 , Sox2 , 
Nanog , and LIN28 . 
[ 0181 ] In some cases , cells cultured using a method of the 
present disclosure are somatic stem cells ( also known as 
“ adult stem cells ” ) . Suitable somatic stem cells include , e . g . , 
tissue stem cells ; and tissue precursor cells . Stem cells that 
can be cultured in a hydrogel composition of the present 
disclosure include , e . g . , neural stem cells , hematopoietic 
stem cells , mammary stem cells , epidermal stem cells , 
intestinal stem cells , mesenchymal stem cells , endothelial 
stem cells , pancreatic stem cells , dermal stem cells , myo 
cardial stem cells , oligodendrocyte precursor cells , neural 
stem cells , olfactory adult stem cells , neural crest stem cells , 
hepatic stem cells , and the like . 
Methods of Differentiating Cells 
[ 0182 ] The present disclosure provides methods of pro 
ducing differentiated cells from a stem cell or a precursor 
cell , the methods comprising culturing a stem cell or pre 
cursor cell in a hydrogel composition of the present disclo 
sure , for a period of time and under conditions suitable for 
inducing differentiation of the stem cell or precursor cell . 
Conditions for inducing differentiation of a stem cell or 
precursor cell depend in part on the desired differentiated 
cell . Conditions can include inclusion in the hydrogel of one 
or more factors that induce differentiation . 
[ 018 ] The present disclosure provides methods of treat 
ing a disease or disorder in an individual in need thereof . In 
some cases , the methods involve culturing cells using a 
method of the present disclosure , as described above ; iso 
lating the cells ; and administering to the individual the 
isolated cells . In some cases , the methods involve implant 
ing into the individual a thermoreversible polymer - cell 
composition of the present disclosure . 
[ 0187 ] Diseases that can be treated using cells cultured in 
a thermoreversible polymer of the present disclosure , or 
using a thermoreversible polymer - cell composition of the 
present disclosure , include , but are not limited to , automim 
mune disease ; diseases for which treatment involves regen 
eration of neural cells / tissue ; diseases for which treatment 
involves regeneration of cardiac cells / tissues ; Parkinson ' s 
Disease ; and Alzheimer ' s Disease . Cells differentiated from 
the stem cells using a method of the present disclosure 
include myocardial cells , insulin - producing cells , neuronal 
cells , oligodendrocytes , and the like ; such cells can be safely 
utilized in stem cell transplantation therapies for treatment 
of various diseases such as heart failure , insulin dependent 
diabetes mellitus , Parkinson ' s disease and spinal cord injury . 
Stem cells , or differentiated cells derived therefrom , can be 
used for autologous cells therapy , wherein the therapy is 
specific ( e . g . , personalized ) for a particular subject . Stem 
cells , or differentiated cells derived therefrom , can be used 
for or non - autologous therapy . 
[ 0188 ] Subjects suitable for treatment with a subject 
method include individuals who have been diagnosed as 
having a blood cell cancer ( e . g . , a leukemia ) ; individuals 
who have been diagnosed with AIDS ; individuals with 
sickle cell anemia ; individuals with an immune disorder , 
e . g . , an acquired immunodeficiency , a genetic immunodefi 
ciency ; individuals with Type 1 diabetes ; individuals with a 
nervous system disorder such as Alzheimer ' s disease , Par 
kinson ' s disease , Huntington ' s disease , Lou Gehrig ' s dis 
ease , spinal cord injury , stroke , etc . ; individuals with a liver 
disorder such as hepatitis , cirrhosis , a metabolic disorder 
affecting the liver or central nervous system ( e . g . , lysosomal 
storage disease ) ; individuals with a disorder of the cartilage 
or bone , e . g . , individuals requiring joint replacement , indi 
viduals with osteoarthritis , individuals with osteoporosis , 
etc . ; individuals with a cardiac disorder , e . g . , myocardial 
infarction , coronary artery disease , or other disorder result 
ing in ischemic cardiac tissue ; individuals with renal disor 
ders , e . g . , kidney failure ( e . g . , individuals on kidney dialy 
sis ) ; individuals with skeletal muscle disorders , such as 
muscular dystrophy ; and individuals with a lung disorder 
such as emphysema , pulmonary fibrosis , idiopathic pulmo 
nary fibrosis , etc . 
Methods of Isolating Cells 
[ 0183 ] The present disclosure provides methods of pro 
ducing a stem cell , a precursor cell , or a differentiated cell , 
the methods comprising : a ) culturing a cell in a hydrogel 
composition of the present disclosure ; and b ) isolating the 
cell from the hydrogel composition . For example , in some 
cases , a cell is cultured in a hydrogel composition of the 
present disclosure at a temperature at which the hydrogel is 
a semi - solid ( e . g . , a gel ) ( e . g . , 37° C . ) ; and the cell , or 
progeny of the cell , is isolated from the hydrogel composi 
tion by reducing the temperature ( e . g . , to about 4° C . ) of the 
hydrogel composition such that the hydrogel composition 
becomes a liquid . A cell can be isolated from a liquid form 
of the hydrogel composition using centrifugation or any 
other means . 
[ 0184 ] In some cases , a method of the present disclosure 
comprises : a ) culturing a stem cell in a hydrogel composi 
tion of the present disclosure at a temperature at which the 
hydrogel is a semi - solid ( e . g . , a gel ) , where the hydrogel 
composition comprises one or more factors that induce 
differentiation of the stem cell ; b ) reducing the temperature 
of the hydrogel composition such that the hydrogel compo 
sition becomes a liquid ; and c ) isolating the differentiated 
cell ( s ) from the liquid . 
[ 0185 ] In some cases , a method of the present disclosure 
comprises : a ) culturing a stem cell in a hydrogel composi 
tion of the present disclosure at a temperature at which the 
hydrogel is a semi - solid ( e . g . , a gel ) , where the hydrogel 
composition comprises one or more factors that promote 
growth and proliferation of the stem cell ; b ) reducing the 
temperature of the hydrogel composition such that the 
hydrogel composition becomes a liquid , and c ) isolating the 
proliferated stem cells from the liquid . 
Utility 
[ 0189 ] The subject thermoreversible polymers , hydrogels 
and methods find use in a variety of applications . Applica 
tions of interest include , but are not limited to , applications 
where the culturing and / or differentiation of cells are of 
interest . Protocols of interest can use single cells or small 
aggregates of stem cells and evenly disperse them through 
out the hydrogel material at cold temperatures . The material 
can then either be spread out onto a two - dimensional surface 
or dropped into warm media in a stirred tank reactor . Upon 
warming to 37° C . , the material can gel and encapsulate the 
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cells . After changing media every day or every other day and 
checking progress of cell growth , the materials can be 
cooled and centrifuged to isolate the cells . 
[ 0190 ] One application of the present disclosure involves 
the proliferation of stem cells . The subject materials find use 
in culturing stem cells for multiple days at high proliferation 
rates . The cells remain pluripotent after growing in the 
subject hydrogels ( see e . g . , Oct4 / Nanog antibody staining in 
FIG . 10 ) . 
[ 0191 ] Another application involves differentiation of 
cells into specific cell types . The subject materials can be 
modified to select a particular hydrogel stiffness that reflects 
a specific tissue environment . In addition , the subject mate 
rials can also incorporate growth factors or other biochemi 
cal cues to guide the differentiation of stem cells down 
specific lineages . Incorporation of these growth factors 
within the material can significantly decrease the amount of 
overall proteins added , thus reducing costs and time during 
media changes as well as increasing the potency and effi 
ciency of the added growth factors . These materials can be 
used for differentiation of stem cells . Growth factors can be 
added to the surrounding media or attached via heparin 
before cells are incorporated into the hydrogel . After suffi 
cient time for differentiating to the correct ( desired ) cell 
type , the cells can be isolated by cooling and centrifugation . 
[ 0192 ] In some applications , the subject materials can be 
modified to be very soft and have a gel transition tempera 
ture very close to body temperature for use in injections . For 
instance , soft gels with differentiated neurons could be 
injected into the brain for cell replacement therapy . The 
subject materials can also be modified for biodegradability , 
so that cells could be grown , differentiated , and injected all 
in one material . The biodegradable links a subject to clear 
out the material after the cells have been administered . 
rials engineered to be thermoreversible provide for cells to 
be incorporated at cold temperatures into a liquid and then 
encapsulated at warm temperatures when the material gels . 
Simple cooling and centrifugation are required to recover 
cells from the material , thus avoiding harmful shear stress 
and pressure changes associated with many other three 
dimensional systems ( FIG . 1 ) . 
[ 0195 ] The materials used are fully synthetic or semi 
synthetic making them fully defined . In order to obtain 
hydrogels with desirable properties including stiffness , gela 
tion temperature , and viscosity , the ratio of hydrophobic and 
hydrophilic components as well as the size of the polymers 
is varied . Chemical functional groups are incorporated 
within these systems to conjugate heparin which can ulti 
mately attach additional proteins , or to conjugate specific 
biochemical molecules such as peptides or proteins . The 
resulting defined , highly tunable , 3D system provides strong 
utility and versatility for desirable 3D stem cell growth and 
differentiation . 
[ 0196 ] Two different systems were developed which have 
similar uses but which include of two different polymer 
families . Synthetic and semi - synthetic materials were used 
as the base of our hydrogel systems to obtain more repro 
ducible physical and chemical properties and to be able to 
molecularly tailor the materials for ultimate needs . Both 
systems utilize Poly ( N - isopropylacrylamide ) ( PNIPAM ) as 
a thermoreversible polymeric segment / component . PNI 
PAM by itself has a lower critical solution temperature ( LCST ) in water or aqueous buffers around 32° C . , meaning 
that it transitions from a soluble state to an insoluble state 
when it is heated above its LCST ( see e . g . , Chiantore et al . , 
Solution Properties of Poly ( N - Isopropylacrylamide ) , Mak 
romol Chem 1979 , 180 , 969 - 973 ) . When the PNIPAM - based 
thermoreversible polymer is attached to other polymers that 
can interact with water , the entire polymer can become 
thermoreversible , i . e . transition from a liquid state to a 
solid / gel state when heated above the LCST . The acrylamide 
groups hydrogen bond with water below the LCST , and 
above the LCST it becomes more favorable for the acryl 
amide groups to hydrogen bond with each other than with 
water , creating hydrophobic domains that can physically 
entangle / crosslink ” the entire gel ( see FIG . 2 ) . [ 0197 ] One polymer system was developed that includes a 
functionalized hyaluronic acid with a PNIPAM - based ther 
moreversible polymer attached . Hyaluronic acid is a natural 
polysaccharide that is found in the extracellular matrix of 
connective tissues . Some of its roles include cell differen 
tiation , tissue hydration , nutrient diffusion , and proteoglycan 
organization . 
[ 0198 ] Another other polymer system that was developed 
is a PNIPAM - based thermoreversible polymer that incorpo 
rates a poly ( ethylene glycol ) ( PEG ) co - monomer and a 
methacrylate group . PEG is also nontoxic and non - immu 
nogenic , does not allow proteins to adhere , and is biocom 
patible . 
[ 0199 ] These polymer systems find use in hydrogels for 
encapsulating and suspending cells in three - dimensional 
bioreactors for scale - up production in tanks . The present 
systems are also well defined , and use biocompatible com 
ponents . This provides for the use of the stem cells cultured 
or differentiated in the subject hydrogels for therapeutic 
purposes in humans . The present systems maintain the 
viability of cells ( e . g . , stem cells ) and avoid harsh methods 
of recovery of the cells from the system . 
EXAMPLES 
[ 0193 ] The following examples are put forth so as to 
provide those of ordinary skill in the art with a complete 
disclosure and description of how to make and use the 
present invention , and are not intended to limit the scope of 
what the inventors regard as their invention nor are they 
intended to represent that the experiments below are all or 
the only experiments performed . Efforts have been made to 
ensure accuracy with respect to numbers used ( e . g . amounts , 
temperature , etc . ) but some experimental errors and devia 
tions should be accounted for . Unless indicated otherwise , 
parts are parts by weight , molecular weight is weight aver 
age molecular weight , temperature is in degrees Celsius , and 
pressure is at or near atmospheric . Standard abbreviations 
may be used , e . g . , bp , base pair ( s ) ; kb , kilobase ( s ) ; pl , 
picoliter ( s ) ; s or sec , second ( s ) ; min , minute ( s ) ; h or hr , 
hour ( s ) ; aa , amino acid ( s ) ; kb , kilobase ( s ) ; bp , base pair ( s ) ; 
nt , nucleotide ( s ) ; i . m . , intramuscular ( ly ) ; i . p . , intraperitoneal 
( ly ) ; s . c . , subcutaneous ( ly ) ; and the like . 
Example 1 : Design of Thermoreversible Polymers 
[ 0194 ] Materials were developed that make cell ( e . g . , stem 
cell ) propagation simple , are fully defined , and biochemi 
cally tunable , e . g . , through the facile incorporation of pro 
teins to guide cell behavior . Systems were designed for ease 
of cell passaging ( i . e . cell recovery ) from one culture to the 
next with minimal steps and avoiding any harsh processes 
that could damage these delicate cells . Fully defined mate 
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[ 0200 ] Three - dimensional systems designed for cell cul 
ture can produce more cells than two - dimensional systems . 
The mechanical and biochemical characteristics of the sub ject hydrogel systems ( e . g . , stiffness and viscosity ) were 
investigated for supporting cell growth in three dimensional 
bioreactors . 
[ 0201 ] The LCST and mechanical properties of the subject 
three - dimensional systems can be tuned based on the size or 
chemical nature of the main polymer and attached modify 
ing agent as well as by varying the ratio of hydrophilic and 
hydrophobic components . The materials can reflect the 
stiffness of different tissue environments to better support 
cell growth or differentiation . The present materials also 
provide for visualization of cells cultured within the opti 
cally clear materials ; cell progress and aggregate size can be 
closely monitored when materials are pipetted into a cell 
culture well . 
[ 0202 ] Biochemical cues that find use in the growth and 
differentiation of cells can be incorporated using chemical 
functionalities for simple attachment of either heparin for 
subsequent protein attachment or other biochemical cues 
like peptides or proteins . These biochemical additions aid 
cell culture by increasing the local concentration and 
potency of proteins of interest as well as limiting the 
occurrence of protein degradation via endocytosis or other 
mechanisms . The overall cost of the system and media can 
thereby be significantly lowered by reducing the amount of 
proteins required in the media . This property can also 
alleviate some of the transport limitations associated with 
three - dimensional systems . Furthermore , the system can be 
further tuned by incorporating biochemical cues that guide 
differentiation into therapeutically relevant cell types . 
[ 0203 ] The thermoreversible PNIPAM - based polymers 
provide for easy cell recovery utilizing gentle processing 
steps of cooling and centrifugation after the cells have been 
encapsulated at warm temperatures . The subject polymers 
provide hydrogels that are easy to handle between 0° C . and 
37° C . At cold temperatures the subject hydrogels are fluid 
enough to be pipettable but viscous enough so that cells do 
not settle before warming step . The transition temperature 
from liquid to gel has also been selected so that the gels do 
not re - liquefy if the temperature drops to room temperature 
but also do not gel immediately above freezing tempera 
tures . The transition from liquid to gel is very quick , 
encapsulating cells in a suspended state , and providing for 
systems with cells to be immediately solidified upon addi 
tion to warm media . 
groups of an agent of interest ( see FIG . 3 ) . The PEG 
component can be varied by changing the length of PEG 
used or by using a heterobifunctional PEG with an amine 
group on one terminal only . A variety of additional func 
tionalities can be incorporated for use in other types of 
chemical conjugation reactions based on the chemical group 
on the end of the PEG chains . [ 0205 ] Initially , hydrogels were prepared using PNIPAM 
and PEG to investigate the range of PEG contents which can 
make gels at 37° C . Increasing PEG content from 9 wt % - 30 
wt % can shift the stiffness of the resulting polymer by 
orders of magnitude lower as well as shift the LCST by more 
than 10° C . [ 0206 ] Butyl methacrylate groups were incorporated onto 
the backbone to lower the LCST and investigate the effect on 
polymer stiffness . Initial tests utilized 3 , 400 MW diamin 
OPEG and the starting poly ( N - acryloxysuccinimide ) - butyl 
methacrylate ( PNASI - BuMeA ) polymer made in 100 % tolu 
ene ( assume 6 kg / mol molecular weight based on 
polyethylene oxide ( PEO ) GPC standards ) . The resulting 
thermosensitive polymers made gels at 37° C . that re 
liquefied upon cooling . However , in some cases the hydro 
gels were too soft for cell culture ; when cells were plated 
within these gels , the vibration forces from moving the plate 
would force all the cells to the middle of the gels and did not 
support healthy cells . Also , the viscosity was too low for 
these materials at cold temperatures , such that upon 
pipetting onto cell culture plates , the material flowed to the 
edges of the well instead of staying intact as a gel . 
[ 0207 ] To address this problem , the same size PNASI 
BuMeA or IsoBuMeA polymer and BuMeA or IsoBuMeA 
content was maintained , but the length of the diaminoPEG 
was changed . For both types of methacrylate copolymers , a 
trend appeared showing an increase in storage modulus with 
longer diaminoPEG polymers ( see FIG . 20 ) Using 10 , 000 
MW diaminoPEG created stable hydrogels at 37° C . 
although the polymers were softer than those made with 
3 , 400 MW PEG . Upon using shorter PEG chains of , e . g . , 
600 , 1000 and 2000 MW , gels would not form no matter the 
amount of PEG that was attached ( see FIG . 4 ) . 
[ 0208 ] Gels were prepared that are stiff enough at 37° C . 
for use in cell cultures , by starting with PNASI - BuMeA 
based polymers made in 100 % benzene ( assume MW ~ 46 
kg / mol ) . These polymers required less material to make a 
gel ( 10 wt /vol % vs . 20 wt / vol % ) and made transparent , stiff 
gels ( ~ 1 kPa G ' ) at 37° C . However , after being held at 37° 
C . for more than 1 hour , these gels did not re - liquify at cold 
temperatures . Changing the concentration in solution to 7 . 5 
or 5 w / v % produced softer gels that did not re - liquefy . 
Variations of the polymers prepared using a solvent mixture 
with 50 % benzene and 50 % toluene ( assume MW ~ 10 
kg / mol ) re - liquefy at cold temperatures but were still soft 
gels . Further synthesis variations using 75 / 25 and 90 / 10 
solvent mixture ratios ( assume MW - 17 and 23 kg / mol ) had 
the same properties as those made with 100 % benzene and 
were the largest polymers ( see FIG . 5 ) . Blending the small 
est and largest size PNIPAM - PEG - BuMeA polymers pro 
duced gels that were stiff and would re - liquefy , but in some 
cases , these blended compositions suffered from water sepa 
ration / excretion from the gel . 
[ 0209 ] After initial preparations of PNASI - BuMeA poly 
mers , variations were prepared by changing the hydrophobic 
sidechain group . A variety of methyl / ethyl / isobutyl meth 
acrylates were utilized . PNASI - methyl / ethyl / isobutyl meth 
Example 2 : PNIPAM - PEG Polymers 
[ 0204 ] In the PNIPAM - PEG system , the hydrophilic PEG 
included in the system increases the LCST and depending on 
PEG length can make the hydrogels softer . Alternatively , 
incorporation of more hydrophobic groups such as meth 
acrylates ( e . g . , butyl / isobutyl / ethyl / methyl methacrylates ) 
can lower the LCST and make the resulting materials stiffer . 
A homobifunctional diamino - PEG was utilized to attach 
PEG groups to the polymer ( via the NHS ester groups of the 
N - acryloxysuccinimide polymer ) ( see FIG . 3 ) . The reactions 
are performed dilute enough so that there is minimal oppor 
tunity for the amine groups to crosslink across different 
polymer chains . The free amines at the terminal of these 
PEG chains can also be used for introducing additional 
chemical functionality or linked modifying agents of inter - 
est , for instance via conjugations with carboxylic acid 
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acrylate polymers made using a solvent blend of 50 / 50 or 
60 / 40 benzene / toluene did not produce gels at 37° C . but 
instead produced solids crashing out of water . Polymers 
made with 80 / 20 or 90 / 10 benzene / toluene solvent ratios 
made stiff , semi - transparent gels that would re - liquefy at 
cold temperatures , however these polymers would dissolve 
when additional warm media was added when the PEG 
chain was 3 , 400 MW ( see FIG . 8 ) . Using a PEG chain of 
10 , 000 MW makes gels that are stiff at 37° C . , re - liquify . 
PNASI - methyl / ethyl / isobutyl methacrylate polymers were 
made using 100 % benzene solvent ( ~ 46 kg / mol ) and pro 
duced clear , stiff gels at 37° C . that would not re - liquefy at 
10 wt / vol % . Increasing alkyl chain length also increased the 
storage modulus ( see FIG . 22 ) . Isobutyl methacrylate gels 
optimized with the appropriate solvent ratio and polymer 
concentration successfully maintained their hydrogel state 
for at least 5 days in cell culture , providing sufficient time for 
cell propagation . Using lower concentrations of 7 . 5 and 5 
w / v % provides for culturing of cells and cell recovery at 
cold temperatures ( see FIG . 7A - 7D and FIG . 23A - 23D ) . 
Human embryonic stem cells ( hESCs ) and / or induced pluri 
potent stem cells ( iPSCs ) were cultured within these gels 
and remained pluripotent after multiple passages ( see FIG . 
24A - 24B ) . The PEG length and content can be moditied as 
desired to alter the LCST and stiftness of these materials 
depending on the cells and desired cell culture . 
be used to functionalize the hylauronic acid with maleimide 
groups via the carboxylic acids ( FIG . 13 ) . PNIPAM polymer 
is synthesized via reversible addition - fragmentation chain 
transfer ( RAFT ) using a chain transfer agent containing a 
thiolcarbonylthio group , which can be cleaved to reveal a 
thiol on each chain end . Butyl methacrylate or other hydro 
phobic methacrylate groups can be included as a co - mono 
mer during the synthesis reaction to create polymers with 
lower LCSTs than PNIPAM alone ( FIG . 14 and FIG . 15 ) . 
PNIPAM - BuMeA - thiols can also be prepared using similar 
methods to those used at the start of the PNIPAM - PEG 
system with PNASI - BuMeA . Addition of isopropylamine to 
make NIPAM groups and cysteamine to make thiols makes 
polymer chains that may have multiple thiols per chain ( FIG . 
16 ) . 
Example 3 : Addition of Modifying Agents 
[ 0210 ] The synthetic scheme for preparation of the PNI 
PAM - PEG - based thermoreversible polymers provides for 
addition of functional components that have free amines for 
reaction with the NHS ester on the PNASI groups . Diamin 
OPEG is used to incorporate PEG into the system and 
isopropylamine is used to incorporate PNIPAM . To make 
simply PNIPAM - PEG - BuMea / IsoBuMeA the reaction is 
finished with excess isopropylamine , but instead it is pos 
sible to add in additional functionality before converting any 
remaining NHS ester sidechain groups into PNIPAM 
sidechain groups . One way to do this is by using cysteamine 
to create thiols along the chains ( FIG . 9 ) . The resulting 
sidechain thiols can then be subsequently reacted with other 
components or modifying agents or biochemical cues after 
the entire polymer has been purified and dried . Heparin incorporation is easily accomplished by functionalizing the 
heparin with N - maleimidocaproic acid hydrazide ( EMCH ) 
so that the maleimide groups of EMCH can undergo 
Michael - addition type reaction with the free thiols on the 
PNIPAM - PEG - methacrylate polymer ( see FIG . 10 and FIG . 
11 ) . Many other chemical functionalities can be used to 
functionalize the polymer before or after purification . Any 
convenient amine - containing bifunctional linker or bio 
chemical cue can be attached to provide additional benefit or 
to chemically attach other components to the polymer after 
purification . Additionally , a free amine on the PEG group 
terminal can be used for chemical conjugation to an agent of 
interest . 
0212 . Many factors affect both the storage modulus and 
the LCST of the final hydrogels . Increasing the molecular 
weight of hyaluronic acid increases the storage modulus ( see 
FIG . 26A ) . Similarly , increasing the weight ratio of PNI 
PAM to hyaluronic acid also increases the storage modulus 
( see FIG . 26B ) . Increasing polymer concentration follows a 
similar trend up to 7 . 5 % w / v % ( FIG . 26C ) . Addition of 
butyl methacrylate co - monomer to the polymeric material 
can decrease the LCST from ~ 30° C . to below room 
temperature ( FIG . 15 ) , however the mol percent of butyl 
methacrylate within the co - monomer must be below 3 . 5 % to 
maintain gel - like properties . This property of the material is 
useful for cell culture since if using gels on plates , the time 
outside the incubator for media changes or imaging could 
allow the material to re - liquefy . Incorporating a component 
to decrease the LCST helps to tailor the material for a 
desired application . Keeping LCST close to body tempera 
ture could be useful for injections , but a lower LCST is 
useful for cell culture or other uses outside the body . 
[ 0213 ] Optimized HA - PNIPAM gels were successfully 
used to culture multiple types of human pluripotent stem 
cells ( hPSCs ) including H1 and H9 LESCs and TCTF iPSCS 
( see FIG . 27A - 27D ) . The gels maintain a favorable envi 
ronment for the cells to replicate and remain pluripotent over 
the course of multiple passages ( see FIG . 28 and FIG . 
29A - 29C ) . In addition , neural stem cells ( NSCs ) can grow 
within these gels and remain multipotent after multiple 
passages ( see FIG . 30A - 30D ) 
[ 0214 ] Changing the ratio of PNIPAM to hyaluronic acid 
can modulate not only the LCST but also the stiffness ( FIG . 
17 ) . Addition of butyl methacrylate co - monomer to the 
polymeric material can decrease the LCST from ~ 30° C . to 
below room temperature ( FIG . 15 ) . This property of the 
material is useful for cell culture since if using gels on plates , 
the time outside the incubator for media changes or imaging 
could allow the material to re - liquefy . Incorporating a com 
ponent to decrease the LCST helps to tailor the material for 
a desired application . Keeping LCST close to body tem 
perature could be useful for injections , but a lower LCST is 
useful for cell culture or other uses outside the body . 
Increasing the size of the hyaluronic acid from 200 kDa to 
1 MDa can drastically increase viscosity at cold tempera 
tures as well as stiffness at 37° C . ( FIG . 18 ) . 
[ 0215 ] Since this system has vinyl sulfone groups avail 
able for thiol chemistry , any biomolecules or biochemical 
functionalized with thiols can attach and provide additional 
biocompatibility . Heparin can be functionalized using 
cysteamine and EDC / HOBT chemistry to introduce che 
moselective thiol groups . This modified heparin agent can 
Example 4 : Hyaluronic Acid - PNIPAM Conjugation 
[ 0211 ] In the hyaluronic acid system , hydroxyl groups on 
the disaccharides are modified to attach vinyl sulfone 
groups . These chemoselective groups can react with thiol 
containing polymers or biochemical cues to functionalize 
the hyaluronic acid ( see FIG . 12 ) . Additionally , EMCH can 
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wherein : 
a , b , c and d are molar fractions of the co - monomers , 
wherein a and c are each greater than 0 ; 
PEG , is a polyethylglycol polymer ; 
Z is an optional terminal functional group or a linked 
modifying agent ; 
Z ? is a functional group or a linked modifying agent ; 
L is a linker ; 
X and X2 are each independently O or NH ; 
R ! is a lower alkyl ; 
R2 is H or methyl ; and 
G ' and G2 are each independently selected from a poly 
mer segment , a terminal group , a linker and a linked 
modifying agent . 
5 . The thermoreversible polymer of claim 4 , described by 
formula ( II ) : 
( II ) 
subsequently be added to the Hyaluronic acid - vinyl sulfone 
PNIPAM system , for example , by attaching the linker of the 
modified heparin , “ HS ” thiol , to the vinyl sulfone group 
( FIG . 19 ) . 02161 Chemical Functionality : [ 0217 ] The polymers incorporate chemical functionality in 
order to attach heparin for subsequent protein attachment or 
other biochemical cues such as peptides . This helps to 
increase local concentration and potency of the proteins and 
limit endocytosis by the cells . Modifying the proteins and 
other attached cues can better reflect the native tissue 
environment and aid cells in replicating or differentiating to 
a specific lineage . 
[ 0218 ] Physical Property Modifications : 
[ 0219 ] The polymeric materials can be altered by their 
relative component ratios and / or chemical makeup in order 
to select a desired physical property . Stiffness at warm 
temperatures and viscosity at cold temperatures can be 
modulated to encapsulate the cells and to better mimic a 
variety of native tissue environments . 
[ 0220 ] Thermoreversibility : 
[ 0221 ] The polymers include thermoreversible compo - 
nents in order to easily recover and passage cells for large 
production . Thermoreversibility eliminates the need to use 
harsh steps to recover cells and instead can minimize 
external stress cells experience during passaging . The tem 
perature at which the materials gel can be selected for ease 
of handling . 
[ 0222 ] While the present invention has been described 
with reference to the specific embodiments thereof , it should 
be understood by those skilled in the art that various changes 
may be made and equivalents may be substituted without 
departing from the true spirit and scope of the invention . In 
addition , many modifications may be made to adapt a 
particular situation , material , composition of matter , pro 
cess , process step or steps , to the objective , spirit and scope 
of the present invention . All such modifications are intended 
to be within the scope of the claims appended hereto . 
What is claimed is : 
1 . A thermoreversible polymer comprising : 
a N - isopropylacrylamide co - monomer ; 
an alkyl [ meth ] acryl [ ate / amide ) co - monomer ; and 
a PEG acrylamide co - monomer . 
2 . The thermoreversible polymer of claim 1 , wherein the 
alkyl [ meth ] acryl [ ate / amide ] co - monomer is an isobutyl 
methacrylate co - monomer . 
3 . The thermoreversible polymer of any one of claims 1 - 2 , 
further comprising a modifying acryl [ ate / amide ] co - mono 
mer comprising a linked functional group or a linked modi 
fying agent . 
4 . The thermoreversible polymer of claim 1 , comprising 
a segment described by formula ( I ) : 
oty t yto 
H?O H?O OH? 
PEGA RP  , RI HILIZ NH2 
wherein G1 , G2 , PEG , R1 , L , Z and a - d are as described 
in claim 4 . 
6 . The thermoreversible polymer of any one of claims 4 - 5 , 
wherein d is 0 . 
7 . The thermoreversible polymer of any one of claims 4 - 6 , 
wherein b > 0 . 
8 . The thermoreversible polymer of claim 7 , wherein : 
a > 0 . 8 ; 
0 . 1 > b > 0 ; and 
0 . 2 > c > 0 . 
9 . The thermoreversible polymer of any one of claims 4 - 7 , 
wherein Rl is selected from the group consisting of methyl , 
ethyl , propyl , butyl , pentyl , isopropyl , isobutyl , isopentyl , 
tert - butyl , cyclopropyl , and cyclobutyl . 
10 . The thermoreversible polymer of any one of claims 
4 - 8 , wherein Z2 is a chemoselective functional group . 
11 . The thermoreversible polymer of any one of claims 
4 - 8 , wherein Z is a linked modifying agent , wherein the 
modifying agent is selected from a heparin , a hyaluronic 
acid , a specific binding member , a peptide , a nucleic acid , 
gelatin , fibronectin , collagen , laminin , bFGF , EGF , insulin , 
progesterone , glucose , SDF thymosin beta - 4 , SHH , Noggin , 
Activin , TGF63 , FGF8 , BDNF , GDNF , NT3 , PDGF - AA and 
IGF - 1 . 
( 1 ) 
I R 
ott 
O HN HN O HN 
PEG , R 
N - Ñ
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12 . The thermoreversible polymer of any one of claims 
4 - 8 , described by formula ( III ) : 
18 . The thermoreversible polymer of claim 17 , wherein 
Z2 comprises the following structure : 
( III ) 
O HN HN 
PEG , 
NH2 
OH 
OS 
TO HO 
?? ?? 
wherein GP , GP , PEG , and a - c are as described in claim 
4 . 
13 . The thermoreversible polymer of claim 11 , wherein : 
a > 0 . 8 ; 
0 . 1 > b > 0 ; and 
0 . 2 > c > 0 . 
14 . The thermoreversible polymer of claim 5 , described 
by the formula ( IV ) : 19 . The thermoreversible polymer of claim 4 - 9 , wherein G ' and / or G2 comprises the following structure : 
Yd oth 
HN HN 
PEG heparin 
NH2 
OH 
TO HO 
OH ?? 
wherein GP , GP , PEG - , L and a - d are as described in claim 
3 . 
15 . The thermoreversible polymer of any one of claims 
4 - 13 , wherein G ? and G ’ are each independently selected 
from a terminal group , a linker and a linked modifying 
agent . 
16 . The thermoreversible polymer of any one of claims 
4 - 10 , wherein Gº , G or Z2 comprise a linked hyaluronic 
acid that is linked via conjugation to the carboxylic acid 
group of a hyaluronic acid monomer . 
17 . The thermoreversible polymer of any one of claims 
4 - 10 , wherein G ! , GP or Z2 comprise the following structure : 
20 . The then the polymente polymer MW of 2 
OH 
20 . The thermoreversible polymer of any one of claims 
1 - 19 , wherein the polymer has a MW of 5 to 500 kDa . 
21 . The thermoreversible polymer of any one of claims 
1 - 18 , wherein the PEG or PEG , has a MW of 2 to 100 kDa . 
22 . A hydrogel composition , comprising : 
a thermoreversible polymer of any one of claims 1 - 21 ; 
and 
a buffered aqueous solution . 
23 . The hydrogel composition of claim 21 , further com 
prising cells . 
24 . The hydrogel composition of claim 22 , wherein the 
cells are stem cells selected from the group consisting of ( a ) 
adult stem cell derived from bone marrow , umbilical tissues , 
or placenta ; ( b ) neural stem cell ; ( c ) a progenitor cell derived 
from an embryonic stem cell ; and ( d ) embryonic stem cell . 
25 . The hydrogel of claim 22 , wherein the thermorevers 
ible polymer is a solid at 20° C . or more . 
26 . The hydrogel of claim 25 , wherein the thermorevers 
ible polymer is a solid at 37° C . 
O HO 
HO 
OH 
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27 . The hydrogel of claim 22 , wherein the thermorevers 
ible polymer is a liquid at 30° C . or less . 
28 . The hydrogel of claim 27 , wherein the thermorevers 
ible polymer is a liquid at 4° C . 
29 . A method of growing cells , the method comprising : 
introducing cells into a hydrogel composition of any one 
of claims 22 - 28 to produce a culturing mixture com 
prising a cell construct ; and 
incubating the culturing mixture under conditions suitable 
for growth of the cells . 
30 . A method of differentiating stem cells , the method 
comprising : 
introducing stem cells into a hydrogel composition of any 
one of claims 22 - 28 to produce a culturing mixture 
comprising a cell construct ; and 
incubating the culturing mixture under conditions suitable 
for differentiation of the stem cells . 
31 . A method of preparing a thermoreversible copolymer 
of any one of claims 1 - 20 , the method comprising : 
co - polymerizing : 
an alkyl methacrylate in which the alkyl is one of 
methyl , ethyl , propyl , butyl , pentyl , isopropyl , isobu 
tyl , isopentyl , tert - butyl , cyclopropyl , and cyclobu 
tyl ; and 
acrylic acid N - hydroxysuccinimide ester to make a 
copolymer comprising an acrylic backbone ; 
contacting the copolymer with isopropylamine to convert 
a first portion of the N - hydroxysuccinimide ester 
groups to N - isopropylamine groups ; and 
contacting the copolymer with a diamino - PEG to convert 
a second portion of the N - hydroxysuccinimide ester 
groups to N - PEG - NH , groups . 
32 . The method of claim 31 , further comprising contact 
ing the copolymer with an amino linker to convert a third 
portion of the N - hydroxysuccinimide ester groups to 
N - linker - Z2 groups , where Z2 is a chemoselective functional 
group . 
* * * * * 
